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To my all in all, the great and mighty God.
Abstract
The usefulness of time-to-event (survival) analysis has made it gain a wide applicability in sta-
tistically modelling research. The methodological developments of time-to-event analysis that
have been widely adopted are: (i) The Kaplan-Meier method, for estimating the survival func-
tion; (ii) The log-rank test, for comparing the equality of two or more survival distributions;
(iii) The Cox proportional hazards model, for examining the covariate effects on the hazard
function; and (iv) The accelerated failure time model, for examining the covariate effects on the
survival function. Nonetheless, in time-to-event endpoints assessment, if subjects can fail from
multiple mutually-exclusive causes, data are said to have competing risks. For competing risks
data, the Fine and Gray proportional hazards model for sub-distributions has gained popularity
due to its convenience in directly assessing the effect of covariates on the cumulative incidence
function. Furthermore, sometimes competing risks data cannot be considered as independent
because of a clustered design; for instance, in registry cohorts or multi-centre clinical trials.
The Fine and Gray model has been extended to the analysis of clustered time-to-event data,
by including random-centre effects or frailties in the sub-distribution hazard.
This research focuses on the analysis of clustered competing risks with an application to the
investigation of the management of pericarditis clinical trial (IMPI) dataset. IMPI is a multi-
centre clinical trial that was carried out from 19 centres in 8 African countries with the principal
objective of assessing the effectiveness and safety of adjunctive prednisolone and Mycobacterium
indicus pranii immunotherapy, in reducing the composite outcome of death, constriction or car-
diac tamponade, requiring pericardial drainage in patients with probable or definite tuberculous
pericarditis. The clinical objective in this thesis is therefore to analyse time to these outcomes.
In addition, the risk factors associated with these outcomes were determined, and the effect of
the prednisolone and M.indcus pranii was examined, while adjusting for these risk factors and
considering centres as a random effect.
Using Cox proportional hazards model, it was found that age, weight, New York Heart As-
sociation (NYHA) class, hypotension, creatinine, and peripheral oedema show a statistically
significant association with the composite outcome. Furthermore, weight, NYHA class, hy-
potension, creatinine and peripherial oedema show a statistically significant association with
death. In addition, NYHA class and hypotension show a statistically significant association
with cardiac tamponade. Lastly, prednisolone, gender, NYHA class, tachycardia, haemoglobin
level, peripheral oedema, pulmonary infiltrate and HIV status show a statistically significant
association with constriction. A value of 0.1 significance level was used to identify variables as
significant in the univariate model using forward stepwise regression method.
The random effect was found to be significant in the incidence of composite outcomes of death,
cardiac tamponade and constriction, and in the individual outcome of constriction, but this
only slightly changed the estimated effect of the covariates as compared to when the random
effect was not considered. Accounting for death as a competing event to the outcomes of cardiac
tamponade or constriction, does not affect the effect of the covariates on these outcomes. In
addition, in the multivariate models that adjust for other risk factors, there was no significant
difference in the primary outcome between patients who received prednisolone, and those who
received placebo, or between those who received M. indicus pranii immunotherapy, and those
who received placebo.
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This chapter gives a general introduction to this study and the motivation for this work. The
objectives and goals of this research are also stated. An overview of the research organisation
is documented in order to orient the intended audience about current research.
1.1 Introduction
Competing risks has been an active research area in Survival Analysis. Survival Analysis which
is also referred to as time-to-event data analysis, is a term used for describing data that measure
the time to a given event of interest. In medical science, an event can be the onset of an illness,
recovery from an illness, death due to a specific cause etc. The two main objectives of Survival
Analysis are to estimate the time-to-event of interest and to assess the relationship between
explanatory variables and time-to-event. The first objective is often analysed using Kaplan
Meier estimate, which is a non-parametric method of estimating survival function. In addition,
the log-rank test can be used to examine the differences between the survival distribution of
two groups. The second objective is often analysed by the use of Cox’s proportional hazards
model (Rao and Schoenfeld, 2007). Cox’s proportional hazards model is a semi-parametric
method of analysis which does not require the specification of any distribution. Alternatively,
it is the parametric proportional hazard model, which assumes that the event time follows a
pre-specified distribution. The parametric forms of the Cox proportional hazards model are
available only for a few regression models such as exponential and Gompertz and Weibull.
In a situation where the proportionality assumption is not satisfied, accelerated failure time
model is the most appropriate model to consider. It provides estimates in terms of survival
instead of hazards of the outcome. The most commonly used distributions are log-normal,
2
log-logistics, exponential and Weibull distributions where the choice of these distributions de-
pends on the highest value of likelihood or lowest value of Akaike’s Information Criterion (AIC).
The standards Survival Analysis focuses on the analysis of the time to an event of interest in
the presence of censoring. A subject is said to be censored if it does not experience the event
of interest at the time of study. There are three specific types of censoring: Right censoring :
It refers to when patients do not experience the event of interest until the end of the study,
drop-out of the study or loss to follow-up. Left censoring : Patients are said to be left censored if
they have already experienced the event of interest before the study begins. Interval censoring :
It refers to when an event occurs at an interval between two points.
In addition, in time-to-event data analysis, there is a possibility of the occurrence of an event
other than the event of interest and this event is referred to as competing risks. Competing
risk is an event which either preludes the event of interest or prevents the event of interest from
occurring, or changes the probability of its occurrence (Pintilie, 2006). A sub-hazard model,
also known as a Fine Gray model (Fine and Gray, 1999), and a cause-specific hazard model
(Prentice et al., 1978) are the two broad models for analysing competing risks data. These
two models were developed from the Cox proportional hazard model (Prentice et al., 1978). A
sub-hazard model is the model that directly associates a covariate effect with the cumulative
incidence function, whilst a cause-specific hazard model associates the covariates effect with
the cause-specific hazard function (Do Ha et al., 2014)
In many applications involving competing risks, individuals may be correlated within clus-
ters because of the unobserved shared factors across individuals. This is referred to as ‘clus-
tered competing risks,’ with ‘clustering’ referring to the potential dependence across individuals
within clusters, (Fine and Gray, 1999). For example, in family studies of hereditary cancer,
parents and children may share genetic and environmental factors. These can lead to familial
correlations in the disease onset. Also, in multi-centre studies, the patient population and re-
ferral pattern in each centre may result in correlated outcomes within centres. The Fine-Gray
model, however, does not take such correlation into account, which can be modelled by the
frailty (or random effect). Thus, Katsahian et al. (2006) have extended the Fine Gray model
to a sub-distribution hazard frailty model with a random centre effect.
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1.2 Motivation
The work in this thesis is motivated by a recent multicentre clinical trial of investigation of the
management of pericarditis (IMPI). The main purpose of this trial was to assess the efficacy
and safety of adjunctive prednisolone and M. indicus pranii immunotherapy in reducing the
composite outcome of death, constriction or cardiac tamponade requiring pericardial drainage
in patients with probable or definite tuberculous pericarditis. Therefore, in the case where a
composite outcome is chosen as the primary outcome, it is strongly recommended that the
individual components be analysed separately by means of the corresponding cause-specific
hazards and sub-distribution hazards, in order to check whether the observed effect for the
composite is clinically meaningful (Chi, 2005). Furthermore, in a multicentre clinical trial,
a clustering problem is inevitable. Indeed, usually not all the important risk factors can be
measured and it is reasonable to assume that at least some of them are shared by patients
treated in the same centre. Therefore, when data arise from multi-centre clinical trials, a
correlation induced by clustering should be taken into account in the analysis, (Katsahian
et al., 2006).
1.3 Aim and objectives
Due to the importance of recognising the effect of frailty in clustered survival data and in
clustered competing risks settings, the main aim of this thesis is to account for centre or cluster
effects in a competing risk analysis. The theoretical objectives of this thesis are as follows:
1. Reviewing the usefulness of various standard survival models and competing risks models
on clustered data.
2. Using appropriate models to explore the effect of different explanatory variables on the
time to an event.
3. Assessing the impact of clustering on the estimate of the explanatory variables.
4. Comparing the use of models with the cluster effect to the use of models without the
cluster effect.
The clinical objectives of this thesis are to:
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1. Obtain risk factors that are associated with the individual and composite outcome of
death, constriction or cardiac tamponade requiring pericardial drainage in patients with
probable or definite Tuberculosis Pericarditis.
2. Examine the effect of the prednisolone and M. indicus pranii treatments while adjusting
for the risk factors and considering centres as cluster effect.
1.4 Structure of the thesis
This thesis report is organized as follows: Chapter 1 presents the general introduction, motiva-
tion and objectives for this thesis. In Chapter 2, the research problem is highlighted. Further-
more, the data source and features are discussed. Chapter 3 discusses relevant functions and
models in the standard event time analysis with one possible outcome and their application
to the IMPI data. In Chapter 4, parametric models in the standard event time analysis and
application to IMPI data are presented. In Chapter 5, the concept of competing risks settings
are described, relevant functions and models used for competing risks data are documented.
The application of the described functions and models on IMPI data followed. Clustered com-
peting risks concepts are discussed in Chapter 6, and the important models used in a clustered
competing risks setting explained. Also presented in this chapter is the application of the IMPI
data. Chapter 7 re-establishes the focus and objective of the thesis, presents the concluding
facts discovered in this thesis, and future work is also presented.
1.5 Chapter summary
The discussion in this chapter offers a general overview of the thesis. Combining several end-
points of interest into a composite increases the effect size and thereby reduces the required
sample size, and the dataset from multiple centres enhance the generality of the result. There
is a need to analyse composite outcomes individually and take into account any correlation
induced by clustering in a multi-centre clinical trial. Hence this research focuses on the anal-
ysis of clustered competing risks with an application to the investigation of the management




Background to research problem and
data introduction
In spite of anti-tuberculosis chemotherapy, tuberculous (TB) pericarditis is one of the main
causes of death or disability in nearly half of those affected. Attenuation of the inflammatory
response in TB pericarditis may improve outcome by reducing cardiac tamponade and pericar-
dial constriction, but there is uncertainty as to whether adjunctive immunomodulation with
corticosteroids and Mycobacterium indicus pranii can safely reduce mortality and morbidity.
This chapter provides background to the research problem, presents important features of the
IMPI clinical trial that was used to assess the effectiveness and safety of prednisolone and M.
indicus pranii in reducing the composite outcome of death, constriction, or cardiac tamponade
requiring pericardial drainage in patients with probable or definite tuberculous pericarditis.
The preliminary analysis on IMPI data is also performed in order to examine the difference in
the mean and proportion of the baseline characteristics observed in the trial.
2.1 Background to research problem
Tuberculosis (TB) is a major global health challenge. It causes illness among millions of people
each year and has almost the same rank as the human immunodeficiency virus (HIV), which
is a dominant cause of death in the world. In 2014, the World Health Organization disclosed
that the approximate number of new TB cases were 9.6 million of which 3.2 million were found
among women, 5.4 million among men and 1.0 million among children. They also reported that
there were 1.5 million TB-related deaths (1.1 million in HIV-negative people and 0.4 million
in HIV-positive people), of which about 890 000 were men, 480 000 were women and 140 000
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were children (WHO, 2015).
A rare manifestation of tuberculosis disease is tuberculous pericarditis, which infects the peri-
cardial membrane i.e. the pericardium that covers the heart. Tuberculous pericarditis which is
caused by mycobacterium tuberculosis, is found in about 1% of deaths that are TB-related and
in 1% to 2% of cases of pulmonary TB (Mayosi et al., 2005). It is a common cause of pericardial
effusion, cardiac tamponade, and constrictive pericardial in developing countries. Pericardial
effusion is characterised by an abnormal accumulation of fluid in the pericardial cavity (Mayosi
et al., 2005). Cardiac tamponade is characterized by the pressure on the heart that occurs when
blood or fluid builds up in the space between the heart muscle and the outer covering sac of the
heart, and constrictive pericarditis is chronic inflammation of the pericardium. Tuberculous
pericarditis is found to be associated with HIV infection (Mayosi et al., 2006). For instance, in
sub-Saharan Africa, at least half the patients with large pericardial effusions are infected with
HIV (Ntsekhe et al., 2008). In the Western Cape Province of South Africa, TB pericarditis
accounted for 70% of cases with large pericarditis effusion (Reuter et al., 2005).
Therapy for TB pericaditis consists of medical treatment with rifampicin, isoniazid, pyrazi-
namide, and ethambutol for 6months, pericardial drainage for cardiac tamponade, and peri-
cardiectomy for pericardial constriction (Mayosi et al., 2002). In spite the use of anti-tuberculosis
chemotherapy, death caused by TB pericarditis remains high (Mayosi, 2007) but, it is even
higher among people with acquired immunodeficiency syndrome (Mayosi et al., 2008). Ad-
ditionally, it was found that the use of glucocorticoid therapy in patients with tuberculous
pericarditis to reduce the inflammatory response, may improve outcomes and decrease the risk
of death by reducing cardiac tamponade and pericardial constriction, but the clinical potency of
adjunctive glucocorticoids is unclear (Mayosi et al., 2014). Meanwhile, Ntsekhe et al. (2003) in-
dicated that there was no assurance as to whether adjunctive glucocorticoid could safely reduce
mortality and morbidity. A meta-analysis of randomized, controlled trials of glucocorticoid
therapy for tuberculous pericarditis showed a nonsignificant reduction in mortality, (Mayosi
et al. (2002), Ntsekhe et al. (2003)), but the numbers of events and patients included were very
small. Mayosi et al. (2014) hypothesized that there would be a large benefit of adjunctive pred-
nisolone for TB pericarditis patients and that intradermal Mycobacterium indicus pranii could
be effective in subduing inflammation and its sequelae in patients with tuberculous pericardi-
tis. M. indicus prani i is a nonpathogenic, saprophytic, rapidly growing atypical mycobacterium
species that has shown clinical benefit when administered as a heat-killed intradermal formula-
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tion in patients with leprosy, and it may have benefits in patients with pulmonary tuberculosis
and HIV infection. There is preliminary evidence indicating that repeated doses of intradermal
heart-killed M. indicus pranii immunotherapy may lessen the inflammation associated with
tuberculosis and increase the CD4+ T-cell count in people infected with HIV (Mathur, 2006).
2.2 Data source
The investigation of the management of pericarditis (IMPI -pronounced “ee-mp-ee” for warrior
in Zulu) is a multicentre international double-blind placebo-controlled randomized trial with 2
x 2 factorial design. It was carried out with the principal objective of assessing the effectiveness
and safety of adjunctive prednisolone and M. indicus pranii immunotherapy, in reducing the
composite outcome of death, constriction or cardiac tamponade requiring pericardial drainage
in patients with probable or definite tuberculous pericarditis . The trial was carried out be-
tween January 2009 and February 2014 in 1400 patients from 19 centres in 8 African countries.
The number of patients per centre varied from 1 to 350 patients. Patients were grouped into
experimental and control groups using central concealed randomization. The experimental
group received oral prednisolone for 6 weeks and an M. indicus pranii injection for 3 months
while the control group received a placebo for the same duration. The other two groups were
those that received the combination of the two therapies and those that received the combi-
nation of the two placebos. The primary outcome is the first occurrence of death, pericardial
constriction, or cardiac tamponade requiring pericardiocentesis and, the secondary outcome is
the safety of immunomodulatory treatment measured by the effect on opportunistic infections
(Mayosi et al., 2014). The IMPI trial was the first largest international multi-centre clinical
trial of patients with TB pericarditis that was adequately powered to determine the effects
of adjunctive immunotherapy on major effectiveness and safety outcomes. The trial design is
described in detail in (Mayosi et al., 2013). The results from the analysis of the data using the
standard Cox proportional hazard model on the effect of the two treatment, shows that the use
of prednisolone for 6 weeks and the use of M. indicus pranii for three months had no significant
effect on the combined outcome of death from all causes, cardiac tamponade requiring pericar-
diocentesis or constrictive pericarditis. Prednisolone tablets and M. indicus pranii injections
were associated with an increased risk of HIV-associated malignancy. The use of prednisolone
reduced the incidence of constrictive pericarditis and hospitalization. The beneficial effects of
prednisolone on constriction and hospitalization were similar in HIV-positive and HIV-negative
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patients.
2.2.1 Exploratory data analysis
A total of 1400 patients were enrolled for the comparison of prednisolone with placebo; 706 were
assigned to receive prednisolone and 694 to receive placebo. The median follow-up period was
636.5 days (interquartile range, 317.5 to 1085.5). Also, a total of 1250 patients were enrolled
for the comparison of M. indicus pranii with placebo; 625 were assigned to receive M. indicus
pranii and 625 to receive placebo. The median follow-up period was 720.5 days (interquartile
range, 368.0 to 1095.0). The baseline characteristics of the treatment groups were similar
across the treatment groups (see Table 2.1 - Table 2.2, p-value >0.05). Out of 1400 patients,
336 patients experienced the composite event, (i.e. death, cardiac tamponade or constriction),
246 patients experienced death, 50 patients experienced cardiac tamponade and 85 patients
experienced constriction. Furthermore, out of 50 patients who had cardiac tamponade, 36%
experienced death and out of 85 patients that have constriction, 27% experience death. Out
of 246 patients that died, 92.7% did not have cardiac tamponade and 90.7% did not have
constriction. Approximately two thirds of the patients had a large pericardial effusion, about
32.9% had pulmonary infiltrate, and two thirds were HIV-positive. 72.4% of the total patients
were from South African centres.
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Table 2.1: Summary statistics for the baseline characteristics of patients randomised to either
prednisolone group or placebo group.
Characteristic Overall Prednisolone Placebo p-value
(N = 1400) (N = 706) (N = 694)
Age (years), Median (IQR) 35.56 (17.66) 35.90 (17.63) 35.38 (17.70) 0.763
Duration of symptoms (days), Median (IQR) 30.00 (28.00) 30.00 (46.00) 30.00 (22.00) 0.396
Weight (kg), Median (IQR) 58.00 (16.00) 57.35 (16.00) 58.00 (15.70) 0.705
N (%) N (%) N (%)
Gender 0.493
Male 784 (56.00) 389 (55.10) 395 (56.92)
Female 616 (44.00) 317 (44.90) 299 (43.08)
Country 0.779
South Africa 1014 (72.43) 509 (72.10) 505 (72.77)
other 386 (27.57) 197 (27.90) 189 (27.23)
NYHA Class 0.566
I 256 (18.32) 137 (19.43) 119 (17.20)
II 694 (49.68) 342 (48.51) 352 (50.87)
III 330 (23.62) 163 (23.12) 167 (24.13)
IV 117 (8.38) 63 (8.94) 54 (7.80)
Hypotension (SBP) 0.259
≤ 90 mmHg 106 (7.58) 59 (8.37) 47 (6.77)
> 90 mmHg 1293 (92.42) 646 (91.63) 647 (93.23)
White blood count 0.098
≤ 10 /mm3 1297 (92.91) 662 (94.03) 635 (91.76)
> 10 /mm3 99 (7.09) 42 (5.97) 57 (8.24)
Tachycardia (HR) 0.398
≤ 100 608 (43.49) 314 (44.60) 294 (42.36)
> 100 790 (56.51) 390 (55.40 ) 400 (57.64)
Heamoglobin 0.454
≥ 10 g/dl 645 (46.30) 319 (45.31) 326 (47.31)
< 10 g/dl 748 (53.70) 385 (54.69) 363 (52.69)
Creatinine 0.865
≤ 105 umol/l 1112 (87.42) 564 (87.58) 548 (87.26)
> 105 umol/l 160 (12.58) 80 (12.58) 80 (12.74)
Palpable paradoxus 0.512
No 1130 (80.71) 565 (80.03) 565 (81.41)
Yes 270 (19.29) 141 (19.97) 129 (18.59)
Peripheral oedema 0.917
No 825 (58.93) 417 (59.07) 408 (58.79)
Yes 575 (41.07) 289 (40.93) 286 (41.21)
Pulmonary infiltrates on CXR 0.427
No 856 (67.08) 422 (66.04 ) 434 (68.13)
Yes 420 (32.92) 217 (33.96) 203 (31.87)
Atrial fibrillation on ECG 0.249
No 1001 (94.61) 501 (93.82) 500 (95.42)
Yes 57 (5.39) 33 (6.18) 24 (4.58)
Effusion size 0.672
small 106 (7.80) 50 (7.31) 56 (8.30 )
medium 331 (24.36) 172 (25.15 ) 159 (23.56)
large 922 (67.84) 462 (67.54) 460 (68.15)
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Table 2.1 continued ...
Characteristic Overall Prednisolone Placebo p-value
(N = 1400) (N = 706) (N = 694)
N (%) N (%) N (%)
HIV status 0.916
Positive 939 (67.07) 474 (67.14) 465 (67.00)
Negative 431 (30.79) 218 (30.88) 213 (30.69)
Unknown 30 (2.14) 14 (1.98) 16 (2.31)
Tamponade at presentation 0.912
No 423 (43.21) 213 (43.38) 210 (43.03)
Yes 556 (56.79) 278 (56.62) 278 (56.97)
Constriction at presentation 0.481
No 559 (55.90) 279 (54.81) 280 (57.03)
Yes 441 (44.1) 230 (45.10) 211 (42.79)
* SD: Standard Deviation; NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR:
Chest Xray.
* Mann-Whitney test was used to test for a significant difference in the means of the continuous variables and chi-square
was used to test for a significant difference in the proportion of discrete variables.
Table 2.2: Summary statistics for the baseline characteristics of patients randomized to either
M. indicus pranii group or placebo group.
Characteristic Overall M. indicus pranii Placebo p-value
(N = 1250) (N = 625) (N = 625)
Age (years), Median (IQR) 35.56 (17.60) 34.94 (16.94) 35.72 (19.14) 0.171
Duration of symptoms (days), Median (IQR) 30.00 (28.00) 30.00 (41.00) 30.00 (27.00) 0.243
Weight (kg), Median (IQR) 58.00 (16.00) 57.00 (15.40) 58.00 (15.00) 0.160
N (%) N (%) N (%)
Gender 0.099
Male 695 (55.60) 333 (53.28) 362 (57.92)
Female 555 (44.40) 292 (46.72) 263 (42.08)
Country 0.802
South Africa 896 (71.68) 446 (71.36) 450 (72.00)
other 354 (28.32) 179 (28.64) 175 (28.00)
NYHA Class 0.890
I 234 (18.77) 121 (19.39) 113 (18.14)
II 617 (49.48) 309 (49.52) 308 (49.44)
III 290 (23.26) 144 (23.08) 146 (23.43)
IV 106 (8.50) 50 (8.01) 56 (8.99)
Hypotension (SBP) 0.088
≤ 90 mmHg 94 (7.53) 55 (8.80) 39 (6.25)
> 90 mmHg 1155 (92.47) 570 (91.20) 585 (93.75)
White blood count 0.975
≤ 10 /mm3 1156 (92.78) 576 (92.75) 580 (92.80)
> 10 /mm3 90 (7.22) 45 (7.25) 45 (7.25)
Tachycardia (HR) 0.397
≤ 100 562 (45.03) 274 (43.84) 288 (46.23)
> 100 686 (54.97) 351 (56.16) 335 (53.77)
Heamoglobin 0.209
≥ 10 g/dl 575 (46.22) 276 (44.44) 299 (47.99)
< 10 g/dl 669 (53.78) 345 (55.56) 324 (52.01)
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Table 2.2 continued ...
Characteristic Overall M. indicus pranii Placebo p-value
(N = 1250) (N = 625) (N = 625)
N (%) N (%) N (%)
Creatinine 0.526
≤ 105 umol/l 981 (87.20) 491 (87.84) 490 (86.57)
> 105 umol/l 144 (12.80) 68 (12.16) 76 (13.43)
Palpable paradoxus 0.478
No 1002 (80.16) 506 (80.96) 496 (79.36)
Yes 248 (19.84) 119 (19.04) 129 (20.64)
Peripheral oedema 0.909
No 730 (58.40) 366 (58.56) 364 (58.24)
Yes 520 (41.60) 259 (41.44) 261 (41.76)
Pulmonary infiltrates on CXR 0.218
No 753 (66.05) 366 (64.32) 387 (67.78)
Yes 387 (33.95) 203 (35.68) 184 (32.22)
Atrial fibrillation on ECG 0.777
No 891 (94.69) 446 (94.89) 445 (94.48)
Yes 50 (5.31) 24 (5.11) 26 (5.52)
Effusion size 0.071
small 97 (8.02) 57 (9.47) 40 (6.58)
medium 294 (24.30) 154 (25.58) 140 (23.03)
large 819 (67.69) 391 (64.95) 428 (70.39)
HIV status 0.112
Positive 840 (67.20) 437 (69.92) 403 (64.48)
Negative 384 (30.72) 175 (28.00) 209 (33.44)
Unknown 26 (2.08) 13 (2.08) 13 (2.08)
Tamponade at presentation 0.102
No 386 (43.67) 201 (46.44) 184 (40.98)
Yes 498 (56.33) 233 (53.56) 265 (59.02)
Constriction at presentation 0.349
No 503 (55.70) 242 (54.14) 261 (57.24)
Yes 400 (44.30) 205 (45.86) 195 (42.76)
* SD: Standard Deviation; NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR:
Chest Xray.
* Mann-Whitney test was used to test for a significant difference in the means of the continuous variables and chi-square
was used to test for a significant difference in the proportion of discrete variables.
2.3 Chapter summary
This chapter discussed tuberculous pericarditis being a rare case of tuberculosis, its association
with HIV infection, and some of therapy available for treating tuberculous pericarditis and
its shortcomings. We also talk about the proposal made by Mayosi et al. (2014) that there
would be a large benefit of adjunctive prednisolone for TB pericarditis patients, and that
intradermal Mycobacterium indicus pranii could be effective in subduing inflammation and
its sequelae in patients with tuberculous pericarditis. Presented also in this chapter are the
baseline characteristics of the IMPI clinical trial used to examine the effect of these treatments
on the probable and definite tuberculous pericarditis, and a preliminary analysis on the dataset
was performed. Using the Mann-Whitney test and the Chi-square test of difference in means
and proportion of the patients’ baseline characteristics with respect to the treatment groups,
we found that there were no statistical significant differences between the treatments in the
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baseline characteristics of the patients.
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Chapter 3
Standard statistical methods for the
analysis of time-to-event data
In this chapter, we review basic functions and the Cox proportional hazards model for the
standard survival analysis. Also, we review the concept of frailty in the survival analysis.
We then apply the Cox model to IMPI trial data in order to explore the effect of different
explanatory variables present in the data. Furthermore, we fit a frailty model to the dataset so
as to examine if there is a significant random effect in the dataset and then compare the model
to the standard Cox model. Finally, we perform model checking which includes the verification
of the proportionality assumption.
3.1 Important functions in time-to-event analysis
There are basically four functions of interest in the time-to-event data analyses. These functions
are the probability density function, survival function, hazard function, and the cumulative haz-
ard function.
The random variable for the event time T is positive and its distribution is defined by the
probability density function f(t) or the cumulative density function F (t) with
f(t) = Pr(T = t)
= lim
∆t→0




where F (t) = Pr(T < t) is the probability that the event of interest has occurred before time t.
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The survival function is defined as the probability of surviving from the beginning of a study
to time t and beyond without experiencing the event of interest. It is given as





= 1− F (t).
(3.1.2)
The survival function can be estimated by the popular Kaplan-Meier method (Kaplan and
Meier, 1958). The Kaplan-Meier estimator is the non-parametric estimator of the survival
function in the presence of right censored data. It is a non-parametric estimator because it
does not make assumption with respect to the structure of the distribution. An estimate for









where S(0) = 1 by definition, d(ti) is the number in the study which fail at ti, n(ti) is the
number in the study at ti and at risk that is able to fail at ti.
The hazard function is defined as the conditional probability of an event in a small time interval
from t to t+ ∆t, given that the idividual is still at risk at the beginning of that interval,
λ(t) = lim
∆t→0




The cumulative hazard function can be estimated using the Nelson-Aalen estimator (Nelson,








The probability density function f(t), the survival function S(t) and the hazard function λ(t)





S(t) = 1− F (t), log(S(t)) = log(1− F (t))



















3.2 The Cox proportional hazards model
The most popular regression model for event time data is the Cox proportional hazards model
introduced by (David Cox, 1972). It is also known as a semi-parametric model because it
makes no assumption about the baseline hazard function, h0(t), but assumes parametric form
for the effect of the covariates on the hazard. The Cox proportional hazards model relies on
the assumption that the hazard, given explanatory variables, is proportional to a given baseline
hazard function and that each of the p covariates under consideration has a linear effect on
the logarithm of the hazard rate, given the other covariates. The Cox regression model can be
written as
hi(t) = h0(t) exp(β
′xi), (3.2.1)
where h0(t) is the baseline hazard function, β
′xi = β1x1i+β2x2i+ · · ·+βpxpi, β′ = (β1, . . . , βp)
are unknown regression coefficients of the p covariates X1, . . . , Xp. xji is the value of the jth
covariate for the ith individual, i = 1, . . . , n, j = 1, . . . , p. The exponential coefficients eβj are
known as hazard ratios.








= exp(β′(xi − xj)). (3.2.2)
3.2.1 Parameter estimation in the Cox proportional hazards model
The regression parameters β in equation (3.2.1) can be estimated using the method of maximum
likelihood. Let t1, t2, . . . , tn be the observed survival time for n individuals, if there are r failures
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at the time points t1 < t2 < · · · < tr−1 < tr and Rj is the risk set at time tj then the partial








where Rj = {i : ti ≥ tj} is the risk set, i.e. the set of subject at risk, at time j and δi is an
indicator, which is zero if the ith survival time ti, i = 1, 2, . . . , n, is right-censored, and unity
otherwise.
The maximum likelihood estimates of the β-parameters in the proportional hazards model
can be found by maximising the corresponding log-likelihood function of equation 3.2.3 using
numerical methods. This maximisation is generally accomplished using the Newton-Raphson
procedure. Most of the major statistical packages such as STATA, R, and SAS have facilities
which enable the proportional hazards model to be fitted.
3.3 Proportional hazard assumption checking
The main assumption of the Cox proportional hazards model is proportional hazards. Pro-
portional hazards implies that the hazard function of one person is proportional to the hazard
function of another person, in other words, the hazard ratio is constant over time. There are a
number of different ways of testing whether a model satisfies the assumption of proportionality
such as adding time-dependent covariates to the Cox model, the graphical method, and tests
based on the Schoenfeld residuals. In this thesis, we shall make use of the Schoenfeld residuals
to examine the proportional hazards assumption which is discussed in detail in Section 3.4.4.
However, if the PH assumption holds for a particular covariate then the Schoenfeld residual
for that covariate will not be related to survival time. So this test is accomplished by finding
the correlation between the Schoenfeld residuals for a particular covariate and the ranking of
individual survival times. The null hypothesis is that the correlation between the Schoenfeld
residuals and the ranked survival time is zero. Rejection of the null hypothesis concludes that
the PH assumption is violated.
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3.4 Model checking
In order to assess the adequacy of a fitted model, there are aspects of a model that require
checking. There is a need to determine whether the model includes an appropriate set of ex-
planatory variables, to see if there are any outlying or influential subjects, and to check if the
proportionality assumption has been satisfied. The model-checking procedures below are based
on residuals. In linear regression methods, residuals are determined as the difference between
an observed data point and predicted or fitted values of the dependent variable. Various resid-
uals that have been defined for the Cox regression model are the Cox-Snell residual, deviance
residual, martingale residual and the Schoenfeld residual.
3.4.1 Cox-Snell residuals
Cox-Snell residuals are a useful means of checking how well the model represents the data. A
survival model is adequate if it represents the survival patterns in the data to an acceptable
degree. This aspect of model checking is known as goodness of fit. The Cox-Snell residual for
ith individual, i = 1, 2, . . . , n, is given by
rci = exp(β̂
′xi)Ĥ0(ti) (3.4.1)
where Ĥ0(ti) is the estimated integrated baseline hazard function or cumulative hazard. This is
also known as Nelson-Aalen estimator. If the model fits the data well then the true cumulative
hazard function condition on the covariate vector has an exponential distribution with hazard
rate of one. If the hazard function follows the 45 degree line then we know that it approximately
has an exponential distribution with a hazard rate of one and that the model fits the data well.
3.4.2 Martingale residuals
Martingale residuals are useful in determining the functional form of the covariates to be in-
cluded in the model. If the test reveals that a covariate can not be included in a model linearly,
then there is a need for such a covariate to be transformed. Assuming X follows the Cox model





zj(s)βdH0(s), j = 1, 2 . . . n.
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zj(s)βdĤ0(s) = δj − rj,
where rj is the Cox-Snell residual.
3.4.3 Deviance residuals
Deviance residuals are useful for examining model accuracy and identifying outliers. The skew
range of Martingale residual makes it difficult to use it to detect outliers. Martingale residuals
have a range between -∞ and 1. For this reason the deviance residuals, which are the Mar-
tingale residuals rescaled so that they are entered around zero, are better to use (Klein and
Moeschberger, 2003). The deviance residual is defined as:
Dj = sign(M̂j){−2[Mj + δj log(δj − M̂j)]}
1
2 ,
where M̂j is martingale residual.
3.4.4 Schoenfeld residuals
Schoenfeld residuals are useful for checking and testing the proportional hazard assumption,
examining leverage points, and identifying outliers. It can be used to descibe each explanatory
variable in the fitted Cox regression model. The Schoenfeld residuals were originally called
partial residuals because the Schoenfeld residuals for the ith individual on the jth explanatory
variable Xj is an estimate of the i
th component of the first derivative of the logarithm of the
partial likelihood function with respect to βj. From equation (3.2.3), this logarithm of the







where xij is the value of the j







The Schoenfeld residual for ith individual of Xj is given by rpji = δi{xji − aji}.
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3.5 Application
In this section, the presented methods of the standard survival analysis were applied to the
IMPI dataset with the goal of identifying various risk factors associated with the composite
outcome of death, cardiac tamponade and constriction and the individual outcomes. We only
present the results of the prednisolone treatment with other risk factors in this section and
other application sections. The results for the M. indicus pranii treatment can be found in the
appendix. This is done so as to reduce the volume of the main thesis that will be generated
through tables and plots from the analysis. However, the interpretations are similar to the
ones presented in the main thesis. The only difference is the replacement of the prednisolone
treatment and its placebo group with the M.indicus pranii treatment and its placebo group.
Also, the effect of the prednisolone and M. indicus pranii treatments were estimated separately
because there was no significant interaction between them (Mayosi et al., 2014). R and STATA
are the software used for analysis in this section and in other application sections of this thesis.
3.5.1 Non-parametric analysis
Prior to formal modelling, Kaplan-Meier plots were used to visually illustrate the survival
distributions in different treatment groups in the study. In Figure 3.1, we observed that the
probability estimate of experiencing the composite outcome in the predinisolone and placebo
groups by 100 days is about 13% and 17% respectively, while the estimate for both groups
to experience death by 100 days is about 9%. Furthermore, the probability of having cardiac
tamponade at day 100 in the predinisolone group is about 3%, while 4% is the estimate in the
placebo group. Also, there is about 4% and 9% probability estimate of having constriction by
100 days for the predinisolone and placebo groups respectively. The ideal way of reporting the
Kaplan-Meier estimate is to present the median survival time, but from the plots in Figure
3.1, the survival curve does not drop to 0.5, hence the median survival time is not calculated.
The plots show that patients in either the prednisolone treatment group or the placebo group
have similar survival distribution over time. However, results from the log-rank test show a
significant difference in the survival distribution of the constriction outcome (p < 0.009). This
result is similar to those presented by Mayosi et al. (2014). In order to have a clear picture of
what happens within a few days of the trial, we also examine the survival distribution over six
months.(Figure 3.2).
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Figure 3.1: Estimated survival function for prednisolone and placebo group until the end of
study. (a) composite outcome, (b) death, (c) constriction, (d) cardiac tamponade.
Figure 3.2: Estimated survival function for prednisolone and placebo group at 6 months of the
study. (a) composite outcome, (b) death, (c) constriction, (d) cardiac tamponade.
3.5.2 Cox proportional hazards models
In order to determine the risk factors associated with the composite outcome, death, constric-
tion and cardiac tamponade, univariate analysis was performed using the regression model
presented in Section 3.2 before proceeding to multivariate models. A value of 0.1 significance
level was used to identify variables as significant in the univariate model using forward stepwise
regression method. We then fit the multivariate Cox proportional hazards model including all
the risk factors and treatment groups. In the univariate and the multivariate proportional haz-
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ards models, age, weight, NYHA class, hypotension (SBP), creatinine, and peripheral oedema
show a statistically significant association with the composite outcome. Also, weight, NYHA
class, hypotension (SBP), creatinine and peripheral oedema show a statistically significant as-
sociation with death. In addition, NYHA class and hypotension (SBP) show a statistically
significant association with cardiac tamponade. Lastly, prednisolone treatment, gender, NYHA
class, tachycardia (HR), Haemoglobin level, peripheral oedema, pulmonary infiltrate and HIV
status show a statistically significant association with constriction.
Tables 3.1 - 3.4 give the results of the four regression models examining the influence of the co-
variates on the hazard rate for composite outcome, death, cardiac tamponade and constriction,
respectively. As observed from the Kaplan-Meier estimates and Mayosi et al. (2014) result, the
prednisolone treatment effect was not associated with the risk of composite outcome, death
and cardiac tamponade even after adjusting for other risk factors in the multivariate Cox PH
models. But, it remained significant in the outcome of constriction as it was in the Kaplan-
Meier estimates. The NYHA class had a significant effect on the hazards rate for all types of
the event, though with a large confidence interval. A comparison between different levels of
creatinine exposed an average hazard ratio for death of 1.82 (95%CI 1.29 to 2.58), signifying
a much higher degree of death event for individuals that have creatinine levels >105 umol/l
compared to patients that have ≤105 umol/l. The effect of hypotension (SBP) is similar in
the death and cardiac tamponade events with a higher effect for patients that have ≤90 mmHg
hypotension level compared to patients that have hypotension level of >90 mmHg. A compar-
ison between patients that have and that do not have pulmonary infiltrate revealed an average
hazard ratio for constriction of 1.55 (95%CI 0.96 to 2.50), indicating a much higher incidence
of constriction for patients that have pulmonary infiltrate compared to patients that do not
have pulmonary infiltrate. HIV status had a significant effect on the hazard of constriction,
with a hazard ratio of 0.52 (95%CI 0.30 to 0.89). This result indicates a lesser incidence of
constriction for HIV-positive patients and suggests that HIV infection is associated with a re-
duced incidence of the development of constrictive pericarditis. Ntsekhe et al. (2008) in his
article titled “HIV Infection Is Associated with a Lower Incidence of Constriction in Presumed
Tuberculous Pericarditis: A Prospective Observational Study,” wrote that this observation sug-
gested that HIV-positive patients have a lower incidence of constriction because the immune
suppression associated with HIV reduces the risk of the development of pericardial fibrosis.
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Table 3.1: Univariate and multivariate Cox PH model for the relative hazard of the com-
posite outcome.
Univariate analysis Multivariate analysis
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.94 (0.76 - 1.17) 0.609 0.94 (0.74 - 1.20) 0.643
Age (years) 1.00 (1.00 - 1.02) 0.030 1.01 (1.00 - 1.02) 0.041
Weight (kg) 0.91 (0.83 - 1.00) 0.042 0.91 (0.81 - 1.00) 0.050
NYHA Class
I 1.00 1.00
II 1.63 (1.12 - 2.37) 0.010 1.46 (0.94 - 2.26) 0.088
III 2.73 (1.86 - 4.01) <0.001 2.38 (1.49 - 3.81) <0.001
IV 3.24 (2.08 - 5.07) <0.001 2.80 (1.65 - 4.75) <0.001
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.59 (0.42 - 0.82) 0.002 0.68 (0.47 - 1.00) 0.050
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.75 (0.60 - 0.93) 0.011 0.87 (0.67 - 1.12) 0.282
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.51 (1.12 - 2.05) 0.006 1.68 (1.20 - 2.35) 0.002
Palpable pulsus paradoxus
No 1.00 1.00
Yes 1.47 (1.15 - 1.88) 0.002 0.88 (0.65 - 1.20) 0.427
Peripheral oedema
No 1.00 1.00
Yes 1.75 (1.41 - 2.17) <0.001 1.44 (1.11 - 1.85) 0.005
Pulmonary infiltrate on CXR
No 1.00 1.00
Yes 1.23 (0.97 - 1.55) 0.087 1.15 (0.89 - 1.49) 0.276
Effusion size
small 1.00 1.00
medium 1.57 (0.93 - 2.64) 0.093 1.69 (0.90 - 3.19) 0.101
large 1.64 (1.00 - 2.69) 0.048 1.55 (0.85 - 2.82) 0.151
AIC 3560.019
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR: Chest Xray.
CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information Criterion
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Table 3.2: Univariate and multivariate Cox PH model for the relative hazard of
death.
Univariate analysis Multivariate analysis
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 1.14 (0.89 - 1.47) 0.298 1.14 (0.87 - 1.47) 0.341
Weight (kg) 0.85 (0.76 - 0.96) 0.006 0.88 (0.78 - 0.98) 0.026
NYHA Class
I 1.00 1.00
II 1.42 (0.93 - 2.16) 0.107 1.27 (0.79 - 2.05) 0.328
III 2.20 (1.42 - 3.43) <0.001 1.87 (1.14 - 3.09) 0.014
IV 3.14 (1.91 - 5.16) <0.001 2.69 (1.55 - 4.66) <0.001
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.45 (0.31 - 0.64) <0.001 0.54 (0.37 - 0.79) 0.002
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.79 (1.28 - 2.52) 0.001 1.82 (1.29 - 2.58) 0.001
Peripheral oedema
No 1.00 1.00
Yes 1.57 (1.23 - 2.02) <0.001 1.40 (1.06 - 1.85) 0.017
AIC 2940.553
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s
Information Criterion
Table 3.3: Univariate and multivariate Cox PH model for the relative hazard of cardiac
tamponade.
Univariate analysis Multivariate analysis
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.78 (0.44 - 1.36) 0.376 0.57 (0.28 - 1.12) 0.104
NYHA Class
I 1.00 1.00
II 3.04 (0.92 - 10.10) 0.069 2.87 (0.65 - 12.58) 0.162
III 4.65 (1.36 - 15.87) 0.014 5.11 (1.15 - 22.73) 0.032
IV 4.86 (1.21 - 19.43) 0.025 6.45 (1.25 - 33.40) 0.026
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.36 (0.17 - 0.74) 0.005 0.39 (0.16 - 0.94) 0.036
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.41 (0.85 - 6.82) 0.098 2.27 (0.79 - 6.46) 0.126
AIC 477.3476
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information
Criterion
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Table 3.4: Univariate and multivariate Cox PH model for the relative hazard of the
constriction.
Univariate analysis Multivariate analysis
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.56 (0.36 - 1.87) 0.010 0.57 (0.35 - 0.92) 0.022
Age (years) 1.01 (1.00 - 1.03) 0.046 1.00 (0.98 - 1.02) 0.898
Gender
Male 1.00 1.00
Female 0.52 (0.32 - 0.82) 0.005 0.57 (0.33 - 0.96) 0.036
NYHA Class
I 1.00 1.00
II 1.93 (0.86 - 4.36) 0.111 1.20 (0.51 - 2.81) 0.682
III 3.85 (1.70 - 8.72) 0.001 2.49 (1.02 - 6.10) 0.045
IV 3.97 (1.54 - 10.24) 0.004 3.03 (1.09 - 8.45) 0.034
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 3.26 (0.80 - 13.27) 0.098 2.61 (0.63 - 10.81) 0.186
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.46 (0.29 - 0.75) 0.002 0.49 (0.29 - 0.85) 0.011
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.40 (0.26 - 0.64) <0.001 0.52 (0.30 - 0.91) 0.021
Palpable pulsus paradoxus
No 1.00 1.00
Yes 1.99 (1.26 - 3.14) 0.003 0.97 (0.54 - 1.74) 0.919
Peripheral oedema
No 1.00 1.00
Yes 2.54 (1.64 - 3.94) <0.001 1.58 (0.94 - 2.67) 0.081
Pulmonary infiltrate
No 1.00 1.00
Yes 1.49 (0.94 - 2.37) 0.090 1.55 (0.96 - 2.50) 0.073
HIV status
Negative 1.00 1.00
Positive 0.41 (0.27 - 0.63) <0.001 0.52 (0.30 - 0.89) 0.017
AIC 954.724
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC:Akaike’s Information
Criterion
3.5.3 Model checking
After a Cox proportional hazards model is fitted, the adequacy of this model, inclusive of both
the proportionality assumption and the goodness of fit, need to be examined. Using Schoenfeld
residuals test (Table 3.5), there is no evidence that the proportionality assumption is violated
for any of the fitted models (p-value > 0.05).
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Table 3.5: Schoenfeld residual global test of
the multivariate models fitted to the different
outcomes for checking proportionality assump-
tion.
Outcomes χ2 df Prob> χ2
Composite 7.69 14 0.9501
Death 5.09 8 0.8002
Cardiac tamponade 3.80 6 0.7035
Constriction 14.86 14 0.3879
df: degree of freedom; χ2 test of statistics
A plot of the Cox-Snell residuals is presented in Figures 3.3 to check the goodness of fit by
residual plots. If the models fit the data perfectly, the graphs would be a straight line through
the origin. In the event of death and composite outcome, the line does not deviate too much
from the reference line, hence the Cox model provides a reasonably good fit for the data. How-
ever, a noticeable deviation of the curve from the 45-degree line was observed in the event of
cardiac tamponade and constriction. It is very common for models with censored data to have
some wiggling at large values of time and it is something which should not cause much concern.
Overall we could conclude that the final models fits the data well.
Figure 3.3: Cox-Snell residual of Cox PH model for (a) composite outcome (b) death (c) cardiac
tamponade (d) constriction.
The plot of deviance residuals against the linear predictors for the composite outcome, death,
cardiac tamponade and constriction event shows that the deviance residuals seem not to be
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symmetrically distributed about zero. There are high or low deviance residuals which suggest
that these subjects may be outliers; (Figure 3.4). Using likelihood displacement values to mea-
sure each subject’s influence on the coefficient vector as a whole, results show some subjects are
influential (Figure 3.5). Likelihood displacement values measure influence by approximating
what happens to the log-likelihood when subject i is omitted. Furthermore, using delta-beta
statistic the results shows that the coefficient does not change when the subjects corresponding
to the largest delta-beta statistics are removed. Therefore, we do not remove the subjects from
the dataset and conclude that there are no influential subjects.
Figure 3.4: Deviance residual of Cox PH model for (a) composite outcome (b) death (c) cardiac
tamponade (d) constriction.
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Figure 3.5: Likelihood displacement plot of Cox PH model for (a) composite outcome (b) death
(c) cardiac tamponade (d) constriction.
3.6 Frailty model
In the analysis of survival data, situations where the survival times are not independent are
frequently encountered. Such data tends to arise when different individuals have some features
in common. As an example, in a multi-centre study, the survival experience of individuals from
the same study centre may be more similar than for individuals from different centres. This
could be because of different surgical teams in the different centres, or different nursing practices
across the centres. Ignoring this heterogeneity in these centres may alter the interpretation and
reporting of the treatment effect.
Frailty models are potential choices for modelling unexplained heterogeneity in a population.
In its simplest form, a frailty is an unobserved random factors that modifies multiplicatively the
hazard function of an individual or a group or cluster of individual. The concept of frailty offers
a way to appropriately introduce random effects in the model to account for association and
unseen heterogeneity. Frailty models extend Cox’s proportional hazards model by introducing
unobserved ‘frailties’ to the model. In this case, the hazard rate will not be just a function of
covariates, but also a function of frailties. The term frailty was introduced by Vaupel et al.
(1979) and it was used in the univariate survival models. Clayton (1978) promoted the model
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further studied by Therneau and Grambsch (2000), Duchateau et al. (2002), and Duchateau
and Janssen (2004), and in Hougaard (2012). The multivariate or shared frailty model is a
conditional independence model in which frailty is common to all subjects in a cluster. The
shared frailty model is responsible for creating dependence between event times. It assumes
that, given the frailty, all event times in a cluster are independent.
The hazard function for the frailty model, either semi-parametric or parametric, can be written
by adding frailty to equation (3.2.1) as
hij(t) = uih0(t) exp(β
′xij), (3.6.1)
where hij is the hazard function for the jth observation from the ith cluster, h0(t) is the un-
specified baseline hazard, xij are the covariates associated with β
′ the regression coefficients,
and ui is the frailty of cluster i. ui are assumed to be independently and identically distributed
from a gamma distribution with mean 1 and unknown variance θ. A Large value of θ indicate
a closer positive relationship between the subjects of the same group and greater heterogeneity
among the groups.
Parametric or non-parametric forms of baseline hazard can be assumed in frailty models just as
it is in the proportional hazards model. If a parametric form of h0(t) is assumed, then maximum
likelihood estimates can be obtained by maximizing the likelihood function using the Newton
Raphson method. But, if a non-parametric form is assumed for h0(t), then the semi-parametric
proportional hazards model is considered and the estimates are usually obtained by using the
Expectation-Maximization (EM) algorithm. These methods basically seek to solve the log-
likelihood in which the frailty, will be integrated out.
3.6.1 Gamma distribution
Gamma distribution is the main frailty distribution widely used in the literature. From a com-
putational and analytical point of view, the gamma distribution is convenient because it is easy
to derive the closed form expressions of survival, density and the hazard function. This is due
to the simplicity of the derivatives of the Laplace transform.
Suppose a random variable T > 0 is gamma distributed with scale parameter β > 0 and shape
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tα−1 exp−βt, t > 0.
3.6.2 Application
In the models presented in Tables 3.6 - 3.9, the heterogeneity parameter θ and the p-value
resulting from the likelihood ratio test comparing the models with and without frailties in the
incidence of composite outcome (θ = 0.078, p-value = 0.048), death (θ = 0.034, p-value =
0.093), cardiac tamponade (θ = 0.070, p-value = 0.326), and constriction (θ = 0.999, p-value
< 0.001) shows that there is a highly significant centre effect in the incidence of constriction
and boardeline significant in the incidence of composite outcome. This was also illustrated by
the distribution of estimated random effects, depicted in Figure 3.6
In comparing the multivariate shared frailty model with the multivariate Cox proportional
hazards models, as presented in Tables (3.1, 3.2, 3.3, and 3.4), it was observed that the same
set of variables are significant in the composite outcome, death, and cardiac tamponade. The
variables have similar estimates. However, there is variability in the significance of variables
in the constriction outcome. The Cox PH model estimates the effect of tachycardia heart rate
and peripheral oedema on the hazard of constriction to be 0.49(95% CI = 0.29 - 0.85, p-value
= 0.011) and 1.58(95% CI = 0.94 - 2.67, p-value 0.081), respectively. On the other hand, the
shared frailty model estimates the effect of tachycardia heart rate and peripheral oedema on
the hazard of constriction to be 0.66(95% CI = 0.38 - 1.17, p-value = 0.144) and 1.77(95% CI
= 1.02 - 3.08, p-value = 0.044), respectively.
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Table 3.6: Multivariable shared frailty model for the relative hazard
of the composite outcome.
Characteristics HR (95%CI) p-value
Treatment
Placebo 1.00
Prednisolone 0.94 (0.74 - 1.19) 0.590
Age (years) 1.01 (1.00 - 1.02) 0.047
Weight (kg) 0.90 (0.81 - 1.00) 0.050
NYHA Class
I 1.00
II 1.44 (0.92 - 2.25) 0.107
III 2.33 (1.44 - 3.76) 0.001
IV 2.39 (1.38 - 4.14) 0.002
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 0.69 (0.47 - 1.01) 0.056
Tachycardia (HR)
≤ 100 mmHg 1.00
> 100 mmHg 0.91 (0.70 - 1.18) 0.472
Creatinine
≤ 105 umol/l 1.00
> 105 umol/l 1.69 (1.20 - 2.37) 0.002
Palpable pulsus paradoxus
No 1.00
Yes 0.89 (0.64 - 1.23) 0.475
Peripheral oedema
No 1.00
Yes 1.51 (1.15 - 1.99) 0.003
Pulmonary infiltrate on CXR
No 1.00
Yes 1.17 (0.91 - 1.52) 0.228
Effusion size
small 1.00
medium 1.62 (0.86 - 3.06) 0.135
large 1.49 (0.81 - 2.72) 0.198
θ (SE) 0.078 (0.072) 0.048
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR: Chest Xray.
CI: Confidence Interval; HR: Hazard Ratio; SE: Standard Error; θ: Heterogeneity parameter
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Table 3.7: Multivariable shared frailty model for
the relative hazard of the death outcome.
Characteristics HR (95%CI) p-value
Treatment
Placebo 1.00
Prednisolone 1.14 (0.87 - 1.49) 0.328
Weight (kg) 0.87 (0.78 - 0.98) 0.024
NYHA Class
I 1.00
II 1.22 (0.76 - 1.98) 0.413
III 1.79 (1.08 - 2.96) 0.024
IV 2.51 (1.43 - 4.42) 0.001
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 0.54 (0.37 - 0.80) 0.002
Creatinine
≤ 105 umol/l 1.00
> 105 umol/l 1.80 (1.27 - 2.55) 0.001
Peripheral oedema
No 1.00
Yes 1.50 (1.12 - 2.01) 0.007
θ (SE) 0.034 (0.039) 0.093
NYHA: New York Heart Association; SBP: Systolic Blood Pressure
CI: Confidence Interval; HR: Hazard Ratio; SE: Standard Error; θ: Heterogeneity
parameter
Table 3.8: Multivariable shared frailty model for the relative
hazard of cardiac tamponade outcome.
Characteristics HR (95%CI) p-value
Treatment
Placebo 1.00
Prednisolone 0.57 (0.28 - 1.13) 0.105
NYHA Class
I 1.00
II 2.80 (0.63 - 12.35) 0.174
III 4.85 (1.08 - 21.79) 0.040
IV 5.79 (1.10 - 30.38) 0.038
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 0.38 (0.16 - 0.92) 0.034
Atrial fibrillation on ECG
No 1.00
Yes 2.28 (0.80 - 6.50) 0.124
θ (SE) 0.070 (0.186) 0.326
NYHA: New York Heart Association; SBP: Systolic Blood Pressure
CI: Confidence Interval; HR: Hazard Ratio; SE: Standard Error; θ: Heterogeneity parameter
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Table 3.9: Multivariable shared frailty model for the relative
hazard of constriction.
Characteristics HR (95%CI) p-value
Treatment
Placebo 1.00
Prednisolone 0.55 (0.34 - 0.91) 0.018
Age (years) 1.00 (0.98 - 1.02) 0.683
Gender
Male 1.00
Female 0.54 (0.32 - 0.93) 0.026
NYHA Class
I 1.00
II 1.47 (0.61 - 3.55) 0.389
III 3.36 (1.34 - 8.39) 0.010
IV 2.57 (0.87 - 7.58) 0.088
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 2.76 (0.65 - 11.67) 0.169
Tachycardia (HR)
≤ 100 mmHg 1.00
> 100 mmHg 0.66 (0.38 - 1.17) 0.144
Haemoglobin
≤ 10 g/dl 1.00
> 10 g/dl 0.54 (0.31 - 0.96) 0.035
Palpable pulsus paradoxus
No 1.00
Yes 0.78 (0.42 - 1.46) 0.434
Peripheral oedema
No 1.00
Yes 1.77 (1.02 - 3.08) 0.044
Pulmonary infiltrate
No 1.00
Yes 1.48 (0.90 - 2.43) 0.125
HIV status
Negative 1.00
Positive 0.56 (0.32 - 0.98) 0.041
θ (SE) 0.999 (0.562) <0.001
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure
CI: Confidence Interval; HR: Hazard Ratio; SE: Standard Error; θ: Heterogeneity parameter
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Figure 3.6: Estimated random effect(s) (frailties) for each centre for the (a) composite outcome,
(b) death, (c) cardiac tamponade, and (d) constriction. In South Africa, there are seven centres
coded as, 101 = Cape Town, 103 = Port Elizabeth, 104 = Mthathia, 105 = Durban, 106 =
Soweto, 107 = Pretoria, 108 = Johannesburg; Mozambique (have one centre coded as, 202 =
Maputo), Malawi (have one centre coded as 301 = Lilongwe), Nigeria (have six centres coded
as 401 = Ibadan, 402 = Kano, 403 = Abeokuta, 404 = Abuja, 405 = Enugun, 406 = Calabar),
Sierra Leone (have one centre coded as 601 = Sierra Leone), Zimbabwe (have one centre coded
as 701 = Harare), Uganda (have one centre coded as 801 = Kampala), and Kenya (have one
centre coded as 901 = Nairobi).
Comparison of Cox PH versus shared frailty model
Table 3.10 gives the log-likelihood, AIC and BIC values of the two models. From the table we
can see that the shared gamma frailty model has both a minimum AIC and BIC value, and
larger log-likelihood, indicating that this model fits the data better than the Cox PH model
which did not take the clustering (centres) effect into account.
Table 3.10: Comparison of Cox PH and shared frailty model.
Cox PH Shared failty
Outcomes `` (model) AIC BIC `` (model) AIC BIC
Composite -1766.01 3560.019 3630.126 -1764.626 3557.252 3627.358
Death -1462.276 2940.553 2981.587 -1461.40 2938.802 2979.837
Cardiac -232.6738 477.3476 507.1267 -232.5717 477.1434 506.9225
Constriction -464.3619 954.7239 1021.353 -456.3408 938.6815 1005.31
``: log-likelihood; AIC: Akaike’s Information Criterion; BIC: Bayesian Information Criterion
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3.7 Chapter summary
In this chapter, we reviewed the probability density function, survival function, hazard function,
and the cumulative hazard function as the important functions in the time-to-event data anal-
ysis. We also reviewed the concept of Cox proportional hazard (PH) model and shared frailty
model for modelling heterogeneity in time-to-event data. These models were implemented to
the IMPI multicentre clinical trial dataset.
Using a 0.1 level of significance, we selected variables (risk factors) that are significant to the
outcomes of interest in the IMPI data i.e. composite outcome and individual outcome of death,
cardiac tamponade and constrictive pericarditis. We then performed a multivariate analysis
using these significant variables and treatment groups. This was considered because the previ-
ous analysis performed on the dataset by Mayosi et al. (2014) only modelled the effect of the
treatments on the outcomes without considering other risk factors. The result of the multivari-
ate analysis shows that prednisolone therapy, as compared with placebo , was associated with
significant reductions in the incidence of constrictive pericarditis. This result also indicates
a lesser incidence of constrictive pericarditis for HIV-positive patients and suggests that HIV
infection is associated with a reduced incidence of the development of constrictive pericarditis.
The proportionality assumption check was done using Schoenfeld residuals; the result shows
that the proportionality assumption was not violated for all the variables. Also, the graph
of Cox-Snell residuals indicated the Cox PH model as a good fit for the data. Furthermore,
results from the shared frailty models show that there is a significant random effect, because
the heterogeneity factor is different from zero, but this only slightly changed the estimated
effect of the covariates as compared to the Cox PH models. In the constrictive pericarditis
event, Tachycardia HR was found to be significant in the Cox model but was insignificant in
the shared frailty model. Also, peripheral oedema was found to be significant in the shared




The most common way of analysing survival data is via the Cox proportional hazards model.
This might be because the model only makes the assumption of proportional hazards, but does
not impose a functional form for the hazard (Collet 2003). However, when the proportional
hazards’ assumption is not tenable, parametric survival models which assume that the event
times follow a specified distribution, can be used. Even though, in this thesis, the propor-
tionality assumption was met for the Cox models presented in Chapter 3, we wish to explore
the parametric approach for completion and comparison purposes. In this section, we review
parametric models for the analysis of time-to-event data. We discuss that if the proportionality
assumption is not satisfied in the Cox model, the parametric model is an alternative option. We
present some event distributions used in the parametric model. We then apply the parametric
proportional model and accelerated failure time model to the IMPI trial data. Furthermore,
parametric proportional models are compared to parametric shared-frailty models. The frailty
model estimation method has been discussed in Section 3.6 of this thesis.
4.1 Parametric proportional hazards models
A parametric proportional hazards model has the same general form as equation (3.2.1) given
above for the Cox regression model. However, a parametric proportional hazards model differs
from a Cox proportional hazards model, in that an event time distribution for the baseline
hazard h0(t) is specified. Also, the coefficients are estimated by a partial likelihood while in
the Cox model, it is estimated by a maximum likelihood. Popular event time distribution are
the exponential, Weibull, and Gompertz distributions.
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4.2 Accelerated failure time models
Although parametric proportional hazards models are very applicable to analyze survival data,
there are relatively few probability distributions for the survival time that can be used with
these models. In these situations, the accelerated failure time (AFT) model is an alternative
to the parametric proportional hazard model for the analysis of survival time data. The AFT
model treats the logarithm of survival time as the response variable and includes an error term
that is assumed to follow a particular distribution. The equation (4.2.1) shows the log-linear
survival time, X1 . . . Xp are explanatory variables with coefficients β1 . . . βp, εi represents resid-
ual or unexplained variation in the log-transformed survival times, while β0 and σ are intercept
and scale parameters, respectively.
log Ti = β0 + β1x1i + · · ·+ βpxpi + σεi, (4.2.1)
An initial step in fitting an AFT model is determining which distribution should be specified for
the survival times Ti (equation 4.2.1). Under the AFT model parametrization, the distribution
chosen for Ti dictates the distribution of the error term εi. For instance, if survival times are
modeled as a Weibull distribution, the error term is assumed to follow an extreme-value distri-
bution. Likewise, if survival times are modeled using the log-logistic or log-normal distribution,
the εi are assumed to be logistic or normal, respectively.
The survivor function of Ti, the random variable associated with the survival time of the i
th
individual, is then:
Si(t) = Pr{Ti ≥ t}
= Pr{exp(µ+ β′xi + σεi) ≥ t}
= Pr{exp(µ+ σεi) ≥ t/ exp(β′xi)}
= S0{t/ exp(β′xi)}.
(4.2.2)
Using the relationship between the hazard and survivor function given in equation 3.1.5 we can




− log[Si(t)] = − log[S0(t/eβ











General forms of the PH and AFT Models
For proportional hazards (PH) models (based on the hazard for one group being proportional





with ψ = exp(α′x)
For the accelerated failure time (AFT) models (based on the survival time of subjects in one
group being a multiple of the survival time of subjects in the other group):
λA(t) = φ
−1λB(t)(t/φ)
with φ = exp(β′x) and:
φ < 1 implies that the time to the vent is accelerated (shorter) and
φ > 1 implies that the time to event is decelerated (longer).
Weibull model is the commonly used model that can be parameterized in both the PH and
AFT metrics.
4.3 Event time distribution
In this section some event time distributions, which are frequently considered for parametric
survival models are summarized.
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4.3.1 Exponential distribution
The exponential distribution is a one-parametric event time distribution implying a time con-
stant hazard rate λ(t) = λ. The density function of the exponential distribution is
f(t) = λ exp(−λt),
and the survival function is
S(t) = exp(−λt).
In a regression model investigating the influence of covariates on the event times, the hazard
rate λ is commonly modelled using
λ = exp(β′x),
to ensure positivity of the estimated hazard rates.
4.3.2 Weibull distribution
The Weibull distribution is defined by the two parameters λ and α, and therefore it is more
flexible than the exponential distribution. Different parametrizations of the Weibull distribution
exist in the literature. One possible formulation of the density function is
f(t) = λα(λt)α−1 exp{−(λt)α},
therefore the exponential distribution is a special case of the Weibull distribution for α = 1.
The survival function for that parametrization is
S(t) = exp{−(λt)α},
and the hazard function can be denoted as
λ(t) = λα(λt)α−1.
4.3.3 Gompertz distribution




and the corresponding hazard function
h(t) = λexp(θt)
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for 0 ≤ t < ∞ and λ > 0. The shape of the hazard function is determined by the parameter
θ. The survival time has an exponential distribution when θ = 0, that is, the exponential
distribution is also a special case of the Gompertz distibution.
4.3.4 Log-logistic distribution
The log-logistic distribution has a fairly flexible functional form. If Y = log(T ) follows logis-
tics distribution with location parameter µ and scale parameter σ having probability density
function
f(y) = σ−1exp((y − µ)/σ)(1 + exp(y − µ)/σ)−2,
then the lifetime T follows a log-logistics distribution with scale parameter α (> 0) and shape
parameter β (> 0) having a probability density function of the form,
f(t) = (β/α)(t/α)β−1(1 + (t/α)β)−2, t > 0
where α = exp(µ) and β = 1/σ. The corresponding hazard and survival functions can be
written as
λ(t) = (β/α)(t/α)β−1(1 + (t/α)β)−1, and
S(t) = (1 + (t/α)β)−1.
The general shape of the hazard function of a log-logistic distribution is very similar to that of
the log-normal distribution.
4.3.5 Log-normal distribution
The log-normal distribution is defined by two parameters λ and α. The density function for a
failure time t can be written as





and the corresponding survival function and hazard function can be written as
S(t) = 1− Φ(α log λt), and λ(t) = f(t)
S(t)
.
where Φ(x) is the cumulative density function of the standard normal distribution.
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4.4 Goodness of fit test for the AFT model
The Cox-Snell residuals’ diagnostic plot can be used to evaluate the overall fit of the AFT model.
The Cox-Snell residuals are calculated by using the cumulative hazard H(ti, β, σ) function and
standardized residual as:
rsi =
log ti − (β̂0 + β̂iXi)
σ̂
,
where β̂0, β̂ and σ̂ are the maximum likelihoods estimates of β0, β and σ respectively.
The Cox-Snell residual can be applied to any parametric model. For the Weibull AFT model,
the Cox-Snell residuals is
rci = exp(rsi).
Cox-Snell residuals for the Log-logistic AFT model will be
rci = log{1 + exp(rsi)}.
For the Lognormal AFT model, Cox-Snell residual is
rci = log{1 + Φ(rsi)},
where Φ(.) is the cumulative distribution function of the standard Normal distribution. In the
Cox-Snell residuals plot, the fitting of the model is good if the plotted points lie on a line that
has an intercept zero and a unit slope.
Another method of assessing the goodness of fit of an AFT model is Akaike’s Information
Criterion (AIC). It can be computed as follows,
AIC = −2`+ 2(b+ d),
where ` =log-likelihood of the model, b, number of parameters of the assumed probability
distribution and d the number of coefficients excluding constant in the final model. A model
with a smaller value of AIC can be considered as a better model compared to other models
under consideration.
4.5 Application
As explained in Section 4.1, the exponential, Weibull, and Gompertz are the popular event-
time distributions used in the parametric proportional hazards model. By using log-likelihood
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and AIC to compare the three distributions, the Weibull distribution was discovered to be a
suitable distribution for the fit of the model because it has the highest log-likelihood and lowest
AIC, hence, Weibull is used as the underline distribution in the model presented in Tables 4.1
- 4.4.
The result of the analysis in Tables 4.1 - 4.4 shows that patients in NYHA class 1, patients that
have hypotension (SBP) >90 mmHg, have creatinine ≤105 umol/l and do not have peripheral
oedema, have lower hazards of the composite outcome. Also, a one-year increase in age increases
the hazard of a composite outcome by 1.01 and a one-kilogram increase in weight increases the
hazard of a composite outcome by 0.90. Furthermore, patients in NYHA class 1, patients that
have hypotension (SBP) >90 mmHg, have creatinine ≤105 umol/l, and do not have peripheral
oedema, have a lower hazards of death. Also, a one-kilogram increase in weight increases the
hazard of death by 0.87. In addition, patients in NHYA class 1 that have hypotension (SBP)
that is >90 mmHg, have lower hazards of cardiac tamponade. Lastly, female patients, patients
in NYHA class 1, patients having tachycardia (HR) >100 mmHg, have haemoglobin >10 g/dl
and patients that are HIV-negative patients have lower hazards of constriction. The Cox-Snell
residuals’ plot for the Weibull PH models shows a deviation from the straight line passing
through the origin (see Figure 4.1) for the composite outcome and the individual outcome of
death, cardiac tamponade and constriction. This indicates that the overall fit of the Weibull
PH model is not a good fit for the data.
The result from the parametric shared frailty model shows that the likelihood ratio test of
H0 : θ̂ = 0, for the hazard of composite outcome and hazard of constriction are significant
(p-value 0.019 and p-value < 0.001 respectively). Meanwhile, the likelihood ratio test was not
significant in the hazards of death and cardiac tamponade (p-value = 0.072 and p-value = 0.212
respectively).
By comparing the Weibull parametric proportional hazards’ model with the Weibull shared
frailty model, the same set of variables was found to be significant to the hazards of the com-
posite outcome, death and cardiac tamponade. On the other hand, in the event of constriction,
a tachycardia (HR) and pulmonary infiltrate was found to be significant in the Weibull para-
metric PH model but was not significant in the Weibull shared frailty model. Also, peripheral
oedema was found to be significant in the Weibull shared frailty model, but not significant in
the Weibull parametric PH model. Table 4.5 gives the log-likelihood, AIC and BIC values of
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the two models. From the Table we can see that the Weibull shared gamma frailty model has
both a minimum AIC and BIC value, and larger log-likelihood, indicating that this model fits
the data better than the Weibull PH model which did not take into account the clustering effect.
Table 4.1: Weibull proportional hazards models with and without frailty in the composite
outcome.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.95 (0.74 - 1.21) 0.664 0.93 (0.73 - 1.19) 0.585
Age (years) 1.01 (1.00 - 1.02) 0.029 1.01 (1.00 - 1.02) 0.032
Weight (kg) 0.90 (0.81 - 1.00) 0.042 0.90 (0.81 - 1.00) 0.039
NYHA Class
I 1.00 1.00
II 1.41 (0.91 - 2.19) 0.122 1.39 (0.89 - 2.16) 0.151
III 2.33 (1.46 - 3.74) <0.001 2.27 (1.40 - 3.67) 0.001
IV 2.72 (1.60 - 4.61) <0.001 2.26 (1.29 - 3.97) 0.004
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.67 (0.46 - 0.98) 0.040 0.67 (0.46 - 0.99) 0.043
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.86 (0.66 - 1.10) 0.231 0.90 (0.69 - 1.17) 0.427
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.71 (1.22 - 2.39) 0.002 1.72 (1.23 - 2.41) 0.002
Palpable pulsus paradoxus
No 1.00 1.00
Yes 0.86 (0.63 - 1.17) 0.332 0.86 (0.63 - 1.19) 0.376
Peripheral oedema
No 1.00 1.00
Yes 1.44 (1.12 - 1.85) 0.005 1.54 (1.17 - 2.04) 0.002
Pulmonary infiltrate on CXR
No 1.00 1.00
Yes 1.15 (0.90 - 1.49) 0.268 1.18 (0.91 - 1.53) 0.220
Effusion size
small 1.00 1.00
medium 1.71 (0.91 - 3.21) 0.097 1.62 (0.86 - 3.06) 0.138
large 1.59 (0.87 - 2.88) 0.131 1.50 (0.82 - 2.76) 0.186
θ (SE) 0.103 (0.084) 0.019
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR: Chest Xray.
CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information Criterion
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Table 4.2: Weibull proportional hazards models with and without frailty in death
outcome.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 1.13 (0.87 - 1.48) 0.366 1.14 (0.87 - 1.48) 0.350
Weight (kg) 0.87 (0.78 - 0.98) 0.023 0.87 (0.78 - 0.98) 0.020
NYHA Class
I 1.00 1.00
II 1.24 (0.77 - 2.00) 0.372 1.20 (0.73 - 1.94) 0.466
III 1.86 (1.13 - 3.06) 0.015 1.77 (1.07 - 2.94) 0.027
IV 2.62 (1.51 - 4.54) 0.001 2.44 (1.38 - 4.31) 0.002
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.54 (0.37 - 0.87) 0.001 0.54 (0.37 - 0.79) 0.002
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.83 (1.29 - 2.58) 0.001 1.80 (1.27 - 2.04) 0.007
Peripheral oedema
No 1.00 1.00
Yes 1.41 (1.07 - 1.86) 0.016 1.51 (1.12 - 2.04) 0.007
θ (SE) 0.039 (0.043) 0.072
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s
Information Criterion
Table 4.3: Weibull proportional hazards models with and without frailty in the cardiac
tamponade outcome.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.56 (0.28 - 1.12) 0.102 0.56 (0.28 - 1.11) 0.099
NYHA Class
I 1.00 1.00
II 2.85 (0.65 - 12.50) 0.164 2.74 (0.62 - 12.12) 0.184
III 5.01 (1.13 - 22.25) 0.034 4.60 (1.01 - 20.88) 0.048
IV 6.24 (1.21 - 32.28) 0.026 5.15 (0.91 - 29.22) 0.065
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.37 (0.15 - 0.89) 0.026 0.35 (0.14 - 6.82) 0.023
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.35 (0.82 - 6.70) 0.110 2.38 (0.83 - 6.82) 0.106
θ (SE) 0.137 (0.230) 0.212
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information
Criterion
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Table 4.4: Weibull proportional hazards models with and without frailty in the constric-
tion outcome.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.56 (0.35 - 0.92) 0.021 0.55 (0.34 - 0.90) 0.018
Age (years) 1.00 (0.98 - 1.02) 0.760 1.01 (0.99 - 1.03) 0.533
Gender
Male 1.00 1.00
Female 0.54 (0.32 - 0.91) 0.022 0.52 (0.30 - 0.90) 0.018
NYHA Class
I 1.00 1.00
II 1.08 (0.46 - 2.54) 0.862 1.29 (0.53 - 3.11) 0.572
III 2.37 (0.96 - 5.80) 0.060 3.09 (1.24 - 7.72) 0.016
IV 2.70 (0.97 - 7.51) 0.057 2.30 (0.78 - 6.74) 0.129
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 2.34 (0.57 - 9.69) 0.239 2.52 (0.59 - 10.64) 0.210
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.47 (0.27 - 0.81) 0.006 0.63 (0.36 - 1.11) 0.112
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.51 (0.29 - 0.89) 0.018 0.55 (0.31 - 0.97) 0.039
Palpable pulsus paradoxus
No 1.00 1.00
Yes 0.93 (0.52 - 1.68) 0.821 0.73 (0.39 - 1.37) 0.331
Peripheral oedema
No 1.00 1.00
Yes 1.59 (0.95 - 2.66) 0.079 1.76 (1.01 - 3.07) 0.045
Pulmonary infiltrate
No 1.00 1.00
Yes 1.57 (0.97 - 2.54) 0.065 1.48 (0.90 - 2.44) 0.122
HIV status
Negative 1.00 1.00
Positive 0.53 (0.31 - 0.91) 0.022 0.55 (0.32 - 0.97) 0.040
θ (SE) 1.030 (0.577) < 0.001
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC:Akaike’s Information
Criterion
Table 4.5: Comparison of Weibull PH and Shared frailty model.
Weibull PH analysis Weibull Shared failty analysis
Outcomes `` (model) AIC BIC `` (model) AIC BIC
Composite -1053.135 2138.27 2218.391 -1050.98 2135.96 2221.089
Death -902.6241 1825.248 1876.541 -901.5556 1825.111 1881.534
Cardiac -215.6668 447.3336 487.0391 -215.3463 448.6927 493.3614
Constriction -370.8102 771.6205 848.4997 -363.0353 758.0706 840.0751
``: log-likelihood; AIC: Akaike’s Information Criterion; BIC: Bayesian Information Criterion
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Figure 4.1: Cox-Snell residual of Weibull proportional hazards model for (a) composite outcome
(b) death (c) cardiac tamponade (d) constriction.
Accelerated failure time model
In order to make the choice of which distribution to use, the identified significant variables in
Section 3.5.2 were fitted using exponential, Weibull, log-logistic and log-normal as the underline
distribution for the accelerated failure time model. The computed value of AIC for a lognormal
AFT model seems to be the better choice as its AIC is less than the rest of the models (see
Table 4.6).
The Q-Q plot is used to check the AFT assumption. The Q-Q plot in Figures 4.2 and 4.3
closely approximates a straight line from the origin which implies the AFT model may provide
an appropriate model. Furthermore, we check the goodness of fit of the model using Cox-Snell
residuals’ plots. The cumulative hazard plot of the Cox-Snell residuals in a lognormal model is
presented in Figure 4.4. The plotted line lies on a line that has a unit slope and zero intercept
in the incidence of death, but there is a noticeable deviation from the straight line passing
through the origin in the incidence of cardiac tamponade and constriction. As a result, there
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Figure 4.2: Q-Q plot of AFT model for time to (a) composite outcome (b) death.
Figure 4.3: Q-Q plot of AFT model for time to (c) cardiac tamponade (d) constriction.
Table 4.6: Comparison of model fit statistics for AFT Models
Models ``(null) ``(model) df AIC
Composite
Exponential -2360.3 -2322.6 15 4675.13
Weibull -2237.6 -2202.1 16 4436.177
Log-normal -2218.6 -2183.5 16 4399.029
Log-logistic -2232.2 -2195.4 16 4422.821
Death
Exponential -2017.1 -1986.6 9 3991.162
Weibull -1954.9 -1925.4 10 3870.851
Log-normal -1945.9 -1916.8 10 3853.588
Log-logistic -1952.9 -1922.4 10 3864.849
Constriction
Exponential -379.1 -370.0 7 754.0975
Weibull -346.0 -337.1 8 690.2262
Log-normal -343.5 -334.9 8 685.7354
Log-logistic -345.8 -336.9 8 689.7931
Cardiac tamponade
Exponential -732.9 -695.8 15 1421.686
Weibull -683.5 -648.2 16 1328.412
Log-normal -677.8 -643.0 16 1318.08
Log-logistic -682.9 -647.1 16 1326.182
``(nul): the log-likelihood for the constant-only model; ``(model): the log-likelihood for the model
df:degree of freedom; df: degree of freedom; AIC:Akaike’s Information Criterion
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Table 4.7: Log-normal accelerated failure time model for the
composite outcome.
Characteristics TR (95%CI) p-value
Treatment
Placebo 1.00
Prednisolone 1.15 (0.68 - 1.95) 0.596
Age (years) 0.98 (0.96 - 1.00) 0.021
Weight (kg) 1.21 (0.97 - 1.53) 0.096
NYHA Class
I 1.00
II 0.41 (0.17 - 0.95) 0.038
III 0.15 (0.06 - 0.39) <0.001
IV 0.10 (0.03 - 0.33) <0.001
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 1.99 (0.80 - 4.92) 0.139
Tachycardia (HR)
≤ 100 mmHg 1.00
> 100 mmHg 1.42 (0.81 - 2.48) 0.218
Creatinine
≤ 105 umol/l 1.00
> 105 umol/l 0.35 (0.16 - 0.77) 0.009
Palpable pulsus paradoxus
No 1.00
Yes 1.21 (0.61 - 2.43) 0.585
Peripheral oedema
No 1.00
Yes 0.46 (0.26 - 0.82) 0.008
Pulmonary infiltrate on CXR
No 1.00
Yes 0.80 (0.46 - 1.40) 0.440
Effusion size
small 1.00
medium 0.36 (0.10 - 1.28) 0.115
large 0.46 (0.14 - 1.53) 0.207
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR: Chest
Xray.
CI: Confidence Interval; TR: Time Ratio; AIC: Akaike’s Information Criterion
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Table 4.8: Log-normal accelerated failure time
model for death outcome.
Characteristics TR (95%CI) p-value
Treatment
Placebo 1.00
Prednisolone 0.73 (0.43 - 1.23) 0.243
Weight (kg) 1.23 (0.98 - 1.54) 0.070
NYHA Class
I 1.00
II 0.55 (0.24 - 1.30) 0.175
III 0.27 (0.11 - 0.68) 0.006
IV 0.14 (0.05 - 0.41) <0.001
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 3.35 (1.41 - 7.94) 0.006
Creatinine
≤ 105 umol/l 1.00
> 105 umol/l 0.30 (0.14 - 0.63) 0.002
Peripheral oedema
No 1.00
Yes 0.51 (0.29 - 0.87) 0.015
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confi-
dence Interval; TR: Time Ratio; AIC: Akaike’s Information Criterion
Table 4.9: Log-normal accelerated failure time model for cardiac
tamponade outcome.
Characteristics TR (95%CI) p-value
Treatment
Placebo 1.00
Prednisolone 5.93 (0.81 - 43.47) 0.008
NYHA Class
I 1.00
II 0.07 (0.002 - 2.65) 0.152
III 0.01 (0.0003 - 0.63) 0.028
IV 0.01 (0.0001 - 0.65) 0.032
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 14.73 (0.77 - 284.32) 0.074
Atrial fibrillation on ECG
No 1.00
Yes 0.09 (0.003 - 2.77) 0.170
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; TR: Time
Ratio; AIC: Akaike’s Information Criterion
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Table 4.10: Log-normal accelerated failure time model for
the constriction outcome.
Characteristics TR (95%CI) p-value
Treatment
Placebo 1.00
Prednisolone 4.11 (1.28 - 13.23) 0.018
Age (years) 1.00 (0.95 - 1.04) 0.727
Gender
Male 1.00
Female 4.39 (1.26 - 15.36) 0.021
NYHA Class
I 1.00
II 0.61 (0.10 - 3.82) 0.598
III 0.12 (0.02 - 0.94) 0.044
IV 0.10 (0.01 - 1.12) 0.061
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 0.10 (0.004 - 2.43) 0.158
Tachycardia (HR)
≤ 100 mmHg 1.00
> 100 mmHg 5.51 (1.46 - 18.17) 0.011
Haemoglobin
≤ 10 g/dl 1.00
> 10 g/dl 3.64 (1.00 - 13.23) 0.050
Palpable pulsus paradoxus
No 1.00
Yes 1.05 (0.24 - 4.54) 0.947
Peripheral oedema
No 1.00
Yes 0.36 (0.11 - 1.19) 0.094
Pulmonary infiltrate
No 1.00
Yes 0.44 (0.14 - 1.44) 0.176
HIV status
Negative 1.00
Positive 5.52 (1.50 - 20.36) 0.010
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval;
TR: Time Ratio; AIC:Akaike’s Information Criterion, HIV: Human Immunodeficiency Virus.
In Tables 4.7 - 4.10, the lognormal AFT model suggests that in the composite outcome, a one-
year increase in age and a one kilogram increase in weight will increase the survival time by
0.98 and 1.21, respectively. Also, patients in NYHA classes I, have creatinine >105 umol/l,
presence of peripheral oedema are factors showing considerable association with survival time in
the composite outcome. An increase in weight, NYHA classes III & IV, hypotension (SBP) >90
mmHg, creatine >105 umol/l, presence of peripheral oedema are factors showing considerable
association with survival time in the outcome of death. Furthermore, the prednisolone group,
NYHA classes III & IV, hypotension (SBP) >90 mmHg, are factors showing considerable asso-
ciation with survival time in the outcome of cardiac tamponade. Patients in the prednisolone
group, female gender, NYHA III & IV, Tachycardia (HR) >100 mmHg, haemoglobin >10 g/dl,
presence of peripheral oedema, HIV-negative patients are factors showing considerable associ-
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ation with survival time in the outcome of constriction.
Figure 4.4: Cox-Snell residual of AFT models for (a) composite outcome (b) death (c) cardiac
tamponade (d) constriction.




In this chapter, we review the use of parametric models for the analysis of time-to-event data.
These models are used instead of the Cox proportional hazards model when the proportionality
assumption for the Cox PH model is not satisfied. In the analysis done in Chapter 3 of
this thesis using a Cox proportional hazards model for IMPI clinical data, we found that the
proportionality assumption was satisfied. However, we explore the use of the parametric model
for completion purposes. Out of the three popular distributions available for the parametric
proportional hazards modelling, the Weibull distribution was found to be a good fit because it
has larger log-likelihood and minimum AIC and BIC. We found that the same sets of variables
are significant in the hazards of the composite outcome, death and cardiac tamponade, but
there is a variation in the significance of variables in the constriction outcome. In the event
of constriction, tachycardia (HR) and pulmonary infiltrate were found to be significant in the
Weibull parametric PH model but was not significant in the Weibull shared frailty model.
Also, peripheral oedema was found to be significant in the Weibull shared frailty model, but
not significant in the Weibull parametric PH model. Heterogeneity parameter θ was found to
be significant in the composite outcome and constriction, but was not significant in the death
and cardiac tamponade. Using log-likelihood and the AIC test shows that the Weibull shared
frailty model fits the data better than the Weibull parametric proportional hazards model.
In addition, we also analysed the dataset using the accelerated failure time model, and the
lognormal distribution was found to be a better distribution for modelling the survival time of




In this chapter, important functions in competing risks settings are discussed. The method of
estimation for competing risks regression coefficients is presented. Regression models based on
different approaches are also discussed. We then apply the cause-specific hazards model and
sub-distribution hazards model to the IMPI trial data.
5.1 Background to competing risk
Competing risks data are common in medical research. They occur as a result of a subject
being exposed to more than one cause of failure. The occurrence of any of the risks of failure
prevents the occurrence of other competing risks or events (Gooley et al., 1999). For example,
patients in a breast cancer study may fail as a result of heart disease or an accident. In this
example, heart disease or an accident are regarded as competing risks because, a patients that
failed as a result of heart disease cannot experience breast cancer. Furthermore, when there are
composite outcomes, it is common to see that an event of interest is competing risk censored
by other events. A composite outcome is as a result of combining several events of interest
within a single outcome. This is done when the required sample size is too large to be realized.
By combining several endpoints of interest into a composite, the intent is to increase the effect
size, thereby reducing the required sample size (Freemantle et al., 2003). Often, this composite
endpoint is the time to the first of several events (Wolbers et al., 2014). In the IMPI clinical trial
dataset considered in this dissertation, the event of interest is the composite outcome of death,
constriction or cardiac tamponade. If we consider constriction as a primary event of interest, it
may be dependently censored by another competing event such as death or cardiac tamponade.
Also, if we choose cardiac tamponade to be the primary event of interest, constriction or death
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can compete against it. Therefore, caution is needed in estimating the probability of the event
of interest occurring in the presence of so-called competing risks.
5.2 The naive Kaplan-Meier estimator
According to medical literature, often the Kaplan-Meier estimator is used in the analysis of
competing risks whereby it views competing events as censored observations. This procedure,
which is sometimes called the ‘naive Kaplan-Meier estimator’ in literature (Putter et al., 2007),
violates one important assumption of the standard Kaplan-Meier estimator, that is the as-
sumption of independence of the censoring distribution, i.e. the distribution of the time to the
competing events. If the competing event time distributions were independent of the distribu-
tion of time to the event of interest, this would imply that at each point in time, the hazard
of the event of interest is the same for subjects that have not yet failed and are still under
follow-up, as for subjects that have experienced a competing event by that time. However, a
subject that is censored because of failure from a competing risk may not experience the event
of interest. Since subjects that will never fail are treated as if they could fail (they are censored),
the naive Kaplan-Meier overestimates the probability of failure and hence underestimates the
corresponding survival probability.
Using the naive Kaplan-Meier estimator, the probability for an event of type k up to a given
time t is estimated by
1− Sk(t) = exp(Λk(t)), (5.2.1)
where Sk(t) can be estimated from the observed data, but cannot be interpreted as a marginal
survival probability, Λk(t) is the cumulative cause-specific hazard. The cumulative incidence
function (CI) is an unbiased estimator when competing risks are present.
5.3 Important functions in the competing risks setting
There are two basic functions used in analyzing competing risk data; the cause-specific (hk(t))
and the cumulative incidence function (Fk(t)).
The cause-specific function for event of type k is the instantaneous risk of dying from a specific
cause k given that the subject is still alive at time t while the cumulative incidence func-
tion for event k, Fk(t) = P (T ≤ t,K = k), can be interpreted as the probability of patients
54
that died from cause k at time t, recognizing the fact that the patient can die from other causes.
Let T = min(T1, . . . , TK) be the time to the first event, and K be the total number of event
types. The cause-specific hazard rate for the kth event type can be defined as
hk(t) = lim
∆t→0














hk(u)S(u)du, k = 1, . . . , K
where S(t) = Pr(T ≥ t) is the overall survival function and Hk(t) =
∫ t
0
hk(u)du is referred to
as the cumulative hazard function. As t → ∞, Fk(t) → Pr(K = k) < 1, hence Fk(t) is not a
proper distribution function. It is thus referred to as a sub-distribution function.
The sub-distribution function was introduced by Gray (1988) in order to define a ‘hazard-
type’ quantity that is directly linked to the cumulative incidence function in the presence of
competing risks. The link between the cumulative incidence function and the sub-distribution
hazard is known from standard survival analysis as
S(t) = 1− F (t) = exp(−Λ(t)), (5.3.3)
where S(t) is the survival function, Λ(t) is the cumulative hazard rate, and F (t) is the cumu-
lative density function.
For the sub-distribution hazard rate of an event type k at time t, individuals that failed from
an event other than k prior to t remain in the risk set. The sub-distribution hazard rate for
the kth event type can be defined as
hk(t) = lim
∆t→0




The condition in the curled brackets are subjects that experience a competing event which are
not removed from the risk set, though they are not really at risk at that time. Interpretation of
the sub-distribution hazard may be seen as problematic, because individuals who experienced
a competing event are not necessarily at risk of experiencing an event of interest.
5.4 Regression models for the competing risks setting
In the presence of competing risks, the most commonly used approaches are the cause-specific
hazards regression proposed by Prentice et al. (1978) and the sub-distribution hazards regression
introduced by Fine and Gray (1999). A computational technique using pseudo-observations,
which was introduced by Andersen et al. (2002) and Klein and Andersen (2005) and binomial
approach suggested by Scheike and Zhang (2008) are other regression approaches in a competing
risks setting, all of which are directly based on cumulative incidence function (Dianatkhah
et al., 2014). Also, the multinonial logistic regression (MNL) model provides an alternative
approach to estimating a competing risks model. It treats the dependent variable as polytomous
qualitative choice variable (Clapp et al., 2006). In ordinary multinomial logistic regression, there
is one equation for predicting each outcome but, in the competing risk set up, there is a different
equation for each outcome in each time point (Jenkins, 2005). A summary of cause-specific and
sub-distribution hazards approaches with an application on IMPI clinical dataset are presented
in this section.
5.4.1 Cause-specific hazard regression model
The regression model for cause-specific hazard (CSH) is based on the Cox proportional hazards
model (David Cox, 1972). The CSH for event type k is a multiplicative function of the baseline
hazard λk;0(t), given a single covariate x:
λk(t|x) = λk;0(t) exp(β′kx), (5.4.1)
where λk;0(t) describes the cause-specific baseline hazard for event type k, x is the p-dimensional
vector of covariates and βk is the vector of regression coefficients of length p for the kth type
of event.
The regression coefficients of the cause-specific hazard model can be obtained by maximizing









The risk set is: Rj = {i : ti ≥ tj}, which includes any individual that has not failed from
any event and is under observation. δi is a censoring indicator returning the value of zero for
a censored subject and a value of one, if any event was noticed. It is an adaptation of the
likelihood function used in standard survival analysis (equation 3.2.3). Hence, an estimation of
regression coefficients can be carried out numerically using the Newton-Raphson method.
5.4.2 Sub-distribution hazards regression model
Fine and Gray (1999) developed another regression model for time-to-event data in the presence
of competing risks. They proposed a Cox-type regression model for the sub-distribution hazard
for an event of interest, in which the effect of covariates can be estimated directly with reference
to the cumulative incidence function. The model is defined as,
λ∗1(t|x) = λ∗1;0(t) exp(β′1x), (5.4.3)
where λ∗1(t|x) denotes the sub-distribution hazard for the event of interest depending on the
vector of covariates x, λ∗1;0(t) is the baseline sub-distribution hazard for an individual with all
covariates equaling zero, and β1 is the vector of regression coefficients.
The exponentiated regression coefficients, eβ, can be obtained from the ratio of two sub-
distribution hazards and are thus also termed sub-distribution hazard ratios, or sub-hazard
ratios. These can be interpreted in a similar way to the hazard ratios in a Cox’s regression
model.
The regression coefficients of the sub-distribution hazard model can be obtained by maximizing









The risk set is: R∗j = {i : (ti ≥ tj) ∪ (ti ≤ tj)}, represent an individual who has not failed
from the cause of interest by time t is at risk. This includes two distinct groups: those who
have not failed from any cause and those who have previously failed from another cause. For
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R∗j = {i : (ti ≤ tj)}, wij ≤ 1: the further ti is from tj the smaller the weight (Pintile, M.
(2006)). These weights are given by the formula: wij = Ĝ(tj)/Ĝ(min(tj, ti)), where Ĝ(.) is the
survivor function for the censoring distribution.
The procedure for estimation of the regression parameters in model (5.4.3) for the sub-distribution
is identical to that for the cause-specific proportional hazards model, the only difference is the
definitions of the risk sets (Fine and Gray, 1999).
5.4.3 Regression models based on pseudo-value approach
A pseudo-value approach is a direct method of modelling of the effects of covariates on the
cumulative incidence function. It was proposed by Anderson et al (2003) as a technique for
modelling state probabilities in multi-state models using pseudo-observations. This technique
was adjusted for the competing risks setting as demonstrated by Klein and Andersen (2005)
since, a competing risks model can be interpreted as a special case of a multi-state model.
Unlike the Fine and Gray model, this approach does not need to establish a proportionality
assumption. The main idea of the approach is to obtain quantities that allow the application
of standard methods for data analysis without consideration of censored subjects.
Estimation method
In general, the pseudo-value approach can be considered to estimate effects of covariates on
any function of events g(T ), if an unbiased estimator θ̂ exists for
θ = E(g(T )). (5.4.5)
For the pseudo-value model approach, a grid of time points τi, . . . , τM is selected. The pseudo-
observations can be estimated for one fixed time point τ0 or for a pre-specified number of time
points τi, . . . , τM . If multiple time points are considered, a nXH−matrix of pseudo observations
is needed. At each grid point, the estimated cumulative incidence function is computed based
on the complete data set Ĝ(τh) and the estimated cumulative incidence function based on the
sample size n − 1 obtained by deleting the ith observation Ĝ(i)(τh) then the pseudo-value for
the ith subject at time τh is defined as:
θ̂ih = nĜ(τh)− (n− 1)Ĝ(i)(τh), i = 1, . . . , n h = 1, . . . ,M (5.4.6)
these are the pseudo-values known from jack-knife techniques. nĜ(t) is the number of events
of type of interest occurring prior to t. When there is no censoring, nĜ(t) is the number of
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events of type 1 occurring prior to t. In this case, θ̂i = (θ̂ih, h = 1, . . . ,M) = (I(Ti ≤ τ1, εi =
1), . . . , I(Ti ≤ TM , εi = 1)) and the θ̂i’s are independent. When there is censoring, the pseudo-
values are close to the indicators and are approximately independent. Thus, this allows to make
use of results from generalized linear models to model the effects of covariates. For regression
purposes, θ̂ih, pseudo-observations can be used as a dependent variable Klein and Andersen
(2005) in a generalized linear model
g(θih|X1) = αh + β′Xi, i = 1, . . . , n, h = 1, . . . ,M. (5.4.7)
where g(.) is a link function as the logit or the complementary log-log function and Xi is the
vector of covariates of subject i. The complementary log-log function when applied to a survival
function gives a proportional hazard representation. A generalized linear model was assumed
with
f(θih) = αh + γ
′Zi = β
′Zih, i = 1, . . . , n h = 1, . . . ,M. (5.4.8)




In the case of multiple time points the generalized estimation equation approach (GEE, Liang
and Zeger, 1986) was proposed for estimation and inference to account for repeated measures
on the same subjects in order to obtain robust and valid standard errors under independent
censoring.
5.5 Application
So far we have analysed IMPI trial data using the standard Cox model and parametric models
by considering the composite event of death, cardiac tamponade or constriction as a single
event of interest and death, cardiac tamponade and constriction individually as the event of
interest. However, there is a need to examine the contribution of competing risks analyses
in the composite outcome setting. In this section, we considered death as a competing risk
to the event of cardiac tamponade and constriction since patient can die before experiencing
these events. We used two main regression approaches in competing risks’ settings, because,
a deeper understanding of competing risks data can be gained by performing both regression
on the cumulative incidence function (CIF) and regression on the cause-specific hazard func-
tions. This approach has been recommended by some authors, among them is (Latouche et al.,
59
2013). Only the result for the effect of the prednisolone treatment with alternative risk factors
is presented in this section and other application sections. The results for the M. indicus pranii
treatment can be found in the appendix. The effects of M. indicus pranii and prednisolone
treatment were estimated separately because there was no significant interaction between them
(Mayosi et al., 2014).
5.5.1 Cumulative incidence function
The primary interest in describing competing risks data is often to estimate the absolute risk of
the occurrence of an event of interest up to a follow-up time point t. Observation from Figure
5.1 of which Figure 5.2 is it’s reduced form shows that the probability of cardiac tamponade
within 100 days is roughly 10% in the prednisolone group and near 11% in the placebo group.
Both probabilities take into account the possibility that death could occur instead. Also, taking
into account the possibility of death, the probability of constriction within 100 days is about
12% in the prednisolone group and roughly 15% in the placebo group. Using gray’s test, the
effect of prednisolone on the hazard of cardiac tamponade when death is a competing event is
not statistically significant (p-value = 0.159) but was significant on the hazard of constriction
when death is a competing event (p-value = 0.0089). These results are similar to when com-
peting event were ignored (see Figures 3.2).
Figure 5.1: Estimated cumulative incidence function for prednisolone and placebo group from
the beginning of study until the end of the study. (a) constriction, (b) cardiac tamponade
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Figure 5.2: Estimated cumulative incidence function for prednisolone and placebo group from
the beginning of study until 6 months. (c) constriction, (d) cardiac tamponade
5.5.2 Competing risks models
The results of multivariate regression models for the cause-specific hazards and the CIFs of the
IMPI clinical trial are displayed in Tables 5.1 and 5.2. The significant risk factors detected in
Section 3 were also used in this section. In comparing the prednisolone group and the placebo
group, a sub-distribution hazard ratio for cardiac tamponade of 0.56 (95 % CI 0.28 - 1.11)
was discovered, suggesting a much lower incidence of cardiac tamponade events for patients
randomised to the predinisolone group compared to patients in the lacebo group. The effect
of cardiac tamponade was lower in patients having hypotension (SBP) of > 90mmHg, 0.40 (95
%CI 0.17- 0.94).
The prednisolone group revealed a sub-distribution hazard ratio for constriction of 0.56 (95
% CI 0.34 - 0.90), indicating a much lower incidence of constriction events for patients ran-
domised to the predinisolone group compared to patients in the placebo group. The effect of
constriction was lower in female patients compared to male patients 0.59 (95 %CI 0.34 - 1.00).
The effect of constriction was lower in patients that have tachycardia (HR) >100mmHg and
haemoglobin >10g/dl. The presence of pulmonary infiltrate in patients was significant to a
constriction event. Also, a comparison between the HIV-positive patient and the HIV-negative
patient revealed a sub-distribution hazard ratio for constriction of 0.52 (95 % CI 0.30 - 0.89),
indicating a much lower incidence of constriction for patients that are HIV-positive to patients
that are HIV-negative.
The effect estimates of covariates on the cause-specific hazard function and the sub-distribution
hazard function are identical. Also, we observed that the estimates of the risk factors from the
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Table 5.1: Multivariate regression models on the cause-specific hazards function and sub-
distribution hazards function on the relative hazard of cardiac tamponade when death is a com-
peting event.
Cause-specific hazards analysis Sub-distribution hazards analysis
Characteristics HR (95% CI) p-value SHR (95% CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.57 (0.28 - 1.12) 0.104 0.56 (0.28 - 1.11) 0.096
NYHA Class
I 1.00 1.00
II 2.87 (0.65 - 12.58) 0.162 2.79 (0.64 - 12.22) 0.172
III 5.11 (1.15 - 22.73) 0.032 4.88 (1.11 - 21.76) 0.038
IV 6.45 (1.25 - 30.40) 0.026 6.03 (1.17 - 31.01) 0.032
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.39 (0.16 - 0.94) 0.036 0.40 (0.17 - 0.94) 0.035
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.27 (0.79 - 6.46) 0.126 2.19 (0.76 - 6.33) 0.147
NYHA: New York Heart Association; SBP: Systolic Blood Pressure
CI: Confidence Interval; HR: Hazard Ratio; SHR: Subdistribution Hazard Ratio; AIC: Akaike’s information criterion
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Table 5.2: Multivariate regression models on the cause-specific hazards function and sub-
distribution hazards function on the relative hazard of constriction when death is a competing
event.
Cause-specific hazards analysis Sub-distribution hazards analysis
Characteristics HR (95% CI) p-value SHR (95% CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.57 (0.35 - 0.92) 0.022 0.56 (0.34 - 0.90) 0.017
Age (years) 1.00 (0.98 - 1.02) 0.898 1.00 (0.98 - 1.02) 0.919
Gender
Male 1.00 1.00
Female 0.57 (0.33 - 0.96) 0.036 0.59 (0.34 - 1.00) 0.048
NYHA Class
I 1.00 1.00
II 1.20 (0.51 - 2.81) 0.682 1.18 (0.50 - 2.78) 0.712
III 2.49 (1.02 - 6.10) 0.045 2.43 (0.99 - 5.95) 0.053
IV 3.03 (1.09 - 8.45) 0.034 2.70 (0.97 - 7.46) 0.056
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 2.61 (0.63 - 10.81) 0.186 2.73 (0.77 - 9.67) 0.120
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.49 (0.29 - 0.85) 0.011 0.51 (0.30 - 0.86) 0.012
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.52 (0.30 - 0.91) 0.021 0.53 (0.30 - 0.93) 0.026
Palpable pulsus paradoxus
No 1.00 1.00
Yes 0.97 (0.54 - 1.74) 0.919 1.00 (0.56 - 1.79) 0.996
Peripheral oedema
No 1.00 1.00
Yes 1.58 (0.94 - 2.67) 0.081 1.54 (0.91 - 2.61) 0.111
Pulmonary infiltrate
No 1.00 1.00
Yes 1.55 (0.96 - 2.50) 0.073 1.55 (0.95 - 2.52) 0.078
HIV status
Negative 1.00 1.00
Positive 0.52 (0.30 - 0.89) 0.017 0.52 (0.30 - 0.89) 0.019
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure
CI: Confidence Interval; HR: Hazard Ratio; SHR: Subdistribution Hazard Ratio; AIC: Akaike’s information criterion
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Table 5.3: Multivariate regression on the cause-specific hazard function of the relative
hazard of death.
Death without cardiac tamponade Death without constriction
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 1.15 (0.87 - 1.51) 0.326 1.22 (0.92 - 1.62) 0.163
Weight (kg) 0.88 (0.78 - 0.99) 0.039 0.86 (0.76 - 0.97) 0.012
NYHA Class
I 1.00 1.00
II 1.29 (0.79 - 2.10) 0.311 1.27 (0.77 - 2.10) 0.349
III 1.88 (1.12 - 3.14) 0.016 1.90 (1.13 - 3.22) 0.016
IV 2.68 (1.52 - 4.74) 0.001 2.63 (1.47 - 4.71) <0.001
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.57 (0.38 - 0.85) 0.006 0.51 (0.34 - 0.75) 0.001
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.75 (1.21 - 2.51) 0.003 1.79 (1.25 - 2.58) 0.002
Peripheral oedema
No 1.00 1.00
Yes 1.35 (1.02 - 1.81) 0.039 1.43 (1.07 - 1.92) 0.017
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information
Criterion
The proportional sub-hazard assumption
The Fine and Gray model relies on the key assumption of the proportionality of sub-hazard.
It is assumed that the sub-distribution hazard ratio does not depend on time. The alternative
way to the proportionality hazards assumption is to allow the hazard ratio to vary over time.
This can be done by introducing to competing risks models 5.4.1 & 5.4.3 variables of the form
zi(t) = zig(t), which vary continuously with time. This method is similar to the one presented
in Section 3.3 of this thesis.
The proportional hazard assumption for the Fine and Gray model was investigated by testing
for time by covariate interaction in the model presented in equation (5.1). The proportionality
assumption for the sub-hazard of cardiac tamponade was met for all the covariates, that is,
there is no significance by treatment interaction, nor by NYHA class, Hypotension and Atrial
fibrillation on ECG. On the contrary, in Table 5.2, the proportionality assumption for the sub-




The analysis of time to event data in the presence of competing risks, i.e. when subjects
can fail from one out of two or more mutually exclusive types of event are considered and
discussed. We examined the effect of the risk factors using a cause-specific hazard model and
sub-distribution hazards model. We believe that a complete understanding of the effect of
a risk factor on competing risk endpoints requires modelling both cause-specific hazards and
sub-distribution hazards side-by-side. The estimates of these risk factors from the standard
multivariate Cox proportional hazards model are the same as the estimates obtained from the
cause-specific hazards model. The effect of these risk factors on both cause-specific hazards
and sub-distribution hazards models are found to be very similar.
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Chapter 6
Clustered competing risk models
The main focus in this research is to analysis clustered competing risks with application to a
multicentre clinical trial. This Chapter discusses an overview of the clustered competing risks
concept, presents the available models used in the clustered competing risks settings, and the
methods of estimation. The models are then applied to the IMPI dataset.
6.1 Overview of clustered competing risks
In the analysis of competing risks data, situation arises where competing risks data cannot be
considered as independent because of a clustered design, such is the case in the registry cohorts
or multicentre clinical trials studies. In the analysis of survival data with clustered design,
frailty models have shown to be useful, where only one risk acts on the population. Studies
have proven that ignoring heterogeneity in centres may alter the interpretation of treatment
effects. Katsahian et al. (2006) have extended Fine and Gray’s model to the case of clustered
data, by including random centre effects or frailties in the sub-distribution hazard model. The
model first allows to assess the heterogeneity across clusters, then incorporates such an effect
when testing the effect of a covariate of interest. Katsahian et al. (2006) used the residual
maximum likelihood approach for the estimation of parameters in their proposed model for
the analysis of clustered competing risks data. In 2011, Katsahian and Boudreau proposed a
penalized partial log-likelihood approach as an alternative estimation method to the one used
by Katsahian et al. (2006). Their proposed method is an extension of Ripatti and Palmgren
(2000) and Therneau et al. (2003) to the case of competing risks. In the analysis of survival
data with clustered design, a penalized partial log-likelihood has been used by Ripatti and
Palmgren (2000) and Therneau et al. (2003) to fit the Gaussian frailty proportional hazards
models. Katsahian and Boudreau (2011) stated that the advantages of their proposed approach
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are that maximization of a penalized partial log-likelihood function can be done using existing
statistical software for Gaussian frailty models and that it is less sensitive to small changes in
the data than the restricted maximum likelihood (REML) method of Katsahian et al. (2006).
Another approach to handling clustered competing risks data is given by Christian et al. (2016)
to infer the cause-specific hazard frailty model for clustered competing risks data using the
hierarchical likelihood method. The hierarchical likelihood incorporates fixed effects as well
as random effects into an extended likelihood function, so that the method does not require
intensive numerical methods to find the marginal distribution like the EM algorithm.
6.2 Frailty model for the cause-specific hazard
Let Ti be the time to failure and ε be the cause of failure. The cause-specific hazard function
for cause k at time t is defined by
hk(t) = lim
∆t→0




Let Yij = min(Tij, Cij), where Tij is the failure time and Cij is the corresponding censoring time
for the jth subject in the ith cluster. Also, let δij = I(Tij ≤ Cij)εij and vi be an unobserved log-
frailty associated with the ith cluster. Following Do Ha et al. (2001), Lee et al. (2014) assume
that given vi, Cij is independent of (Tij, εij) conditional on the covariates xij(j = 1, . . . , ni) and
that given xij and vi, Cij is independent and non-informative on vi. Given vi, the cause-specific
proportional hazards model with a shared frailty conditional on covariates xij is given by
λk(t;xij,vi) = λ0k(t)exp(x
′
ijβk + vi), (6.2.2)
where βk = (βk1, . . . , βkp)
′ is a p x 1 regression parameter vector for cause k, and λ0k(t) is an
unspecified baseline hazard function for cause k. Lee et al. (2014) also assumed that log-frailties
vi ∼ N(0, θ) are independent and follow a distribution with frailty parameter θ.
6.2.1 Estimation procedure and inference
According to Lee and Nelder (1996) and Do Ha et al. (2001), the hierarchical log-likelihood
for the cause-specific proportional hazards model with a shared frailty in equation (6.2.2) is
defined by








where l1ij = l1ij(β1, β2, λ01, λ02;Yij, δij|vi) is a logarithm of the conditional density function for
Yij and δij. l2i is the logarithm of the normal density function vi with parameter θ given by
l2i = l2i(θ; vi) = −
1
2
log 2π − 1
2
log θ − 1
2θ
v2i .
In order to estimate β and v, Lee et al. (2014) used the profile h-likelihood h∗, where λ01 and
λ02 in equation (6.2.3) are eliminated




























is the logarithm of the conditional density function for (Tij, εij)
given υi evaluated at λ̂
s
01 which is the nonparametric maximum HL estimator of λ
s
01 (Do Ha
et al., 2014). d0(k) is the number of type 1 events at t(k).
Following Ha and Lee (2003), the outline of the estimation procedure for fitting the model 6.2.2
is as follows; given a frailty parameter θ, the maximum h-likelihood estimators β̂ and v̂ of β







The asymptotic covariance matrix of β̂ and υ̂ − υ is obtained from the inverse of the observed
information matrix, H∗ = −∂2h∗/∂(β, υ)2, for β and υ based on h∗. Thus, the joint equations
(6.2.6) are solved using the Newton-Raphson method with H∗. For the estimation of θ, Lee











where β̂ = β̂(θ) and v̂ = v̂(θ). Note that pβ,v(h
∗) is a function of θ only because it has already
eliminated β and v from h∗. The restricted maximum likelihood (REML) estimator θ̂ of θ is





Note here that we allow for the ∂v̂/∂θ term when implementing equation (6.2.8). Also, it can









where ξ = −θtr{Ĥ−1(∂Ĥ/∂θ)} and Ĥ = H∗|β=β̂,v=v̂. In summary, the estimates of (β, v) and θ
are obtained by alternating between equations (6.2.6) and (6.2.9) until convergence is achieved.
After convergence, we directly compute the estimates of var(β̂) using the inverse of H∗.
6.3 Frailty model for the sub-distribution hazard
Let Ti be the failure times for subject i and Ci be its corresponding right-censoring times for
i = 1, . . . , n. Also, let εi be the cause of failure for the ith subject, then ε = 0 if Ti > Ci. The
cumulative incidence function of failure from cause 1 is defined as
F1(t) = Pr(Ti ≤ t, εi = 1) (6.3.1)
and the corresponding sub-distribution hazard is given as
h1(t) = lim
∆t→0




note from Section 4.2, that the risk set associated with h1(t) is unusual and differs from the
traditional risk set at time t.
Katsahian and Boudreau (2011) extended the proposed model for the sub-distribution hazard





′β + u) (6.3.3)
where λ10(t) is an unspecified non-negative function time, β is a p x 1 vector of unknown
parameters, and u is a K x 1 vector of frailties. The frailties u1, . . . , uK are assumed to be
Gaussian with mean 0 and unknown variance θ.
6.3.1 Estimation procedure and inference
This section presents the two methods of estimation proposed by (Katsahian et al., 2006) and
(Katsahian and Boudreau, 2011) for the sub-distribution hazard model with frailty. The first
method is the residual maximum likelihood approach and the second method is the penalized
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partial log-likelihood approach.
Residual maximum likelihood approach
This approach involves two main procedures. The first is to find the best linear predictors
(BLUP) of the fixed and random components. The second is to use the results to find the
restricted maximum likelihood (REML) estimators. BLUP can be obtained by maximizing the
sum of the two components of l1 and l2. l1 is the partial log-likelihod of failure times when
uk’s are fixed and l2 is the log-likelihood of the Gaussian random effects, respectively. For the
uncensored observation, l1 can be written as















where Ri = {j : (Ti ≤ Tj) ∪ (Ti > Tj ∩ εj 6= 1)} is the risk set at time Ti. It is comprised of
individuals who have not failed from any cause by Ti, but also those who have previously failed












Using the Newton-Raphson procedure, we can obtain BLUP estimators of β and uk.
In order to carry out the second procedure, only l1 was modified using an inverse probability
of censoring weighting, as originally proposed by Fine and Gray.

















where wj(t) = I(tj ≥ t ∪ εj > 1)Ĝ(t)/Ĝ(tj ∧ t) and Ĝ is the Kaplan-Meier of the survival
function of censoring time. wj(t) = 1 if individuals have not failed, but equal to zero if they
have failed from cause 1 or have been right censored, and below 1 and decreasing overtime if
they failed from another cause.
Penalized partial log-likelihood approach
By extending the penalized partial likelihood (PPL) approach of Gaussian frailty models intro-
duced by Ripatti and Palmgren (2000) and Therneau et al. (2003) to allow for competing risks,
penalized partial log-likelihood (PPLL) can be obtained by summing the partial log-likelihood
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in equation 6.3.4 which is the conditional partial log-likelihood given the frailties and the log-
likelihood function of K i.i.d, N(0, θ) random variable which corresponds to the distribution of
the frailties (equation 6.3.5).
lppll(β, θ, u) = l(β;uk) + l2(θ;u). (6.3.7)
The main interest is in estimating β and θ however, u is a vector of nuisance parameter which
needs to be intergrated out. Now, the integrated penalized partial likelihood of (β, θ) which is
given by






exp(l1 = l(β;uk) + l2(θ;u))du, (6.3.8)
must be computed. With normally distributed frailties, the above K-dimensional integral be-
comes very difficult to solve. Following the methods of (Ripatti and Palmgren, 2000) and
(Therneau et al., 2003) and (Breslow and Clayton, 1993), the Laplace approximation can be
use to solve the integral in the equation (6.3.8).
6.4 Application
Tables 6.1 - 6.4 reports the estimated multivariate risk value of the risk factor analysis on the
patient as well as the centre level, either ignoring or incorporating the random centre effect.
The observed heterogeneity across centres in the rates of constriction is remarkably large (θ
= 0.95 with standard error (SE) = 0.49), in contrast to the heterogeneity in the rates of
cardiac tamponade (θ = 0.16 with SE = 0.18). Large heterogeneity means that event times are
strongly correlated within centres. This was also illustrated by the distribution of estimated
random effects, depicted in Figure 6.1. One might conclude that observed and unobserved
centre-specific factors play a more substantial role in the constriction hazard rates compared
to the competing event rates. Including covariates in the models led to only a small reduction
in centres heterogeneity for the rate of cardiac tamponade of the competing outcomes, with θ
falling to 0.08 but an increase in the rate of constriction, with θ rising to 0.99. Nevertheless,
such a significant random effect only slightly changed the estimated effect of the covariates on
cause-specific hazard and sub-distribution hazard of cardiac tamponade and constriction.
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Table 6.1: Multivariate regression models for with and without frailty on the incidence
of cardiac tamponade when death is a competing risk.
Without frailty With frailty
Characteristics HR (95% CI) p-value HR (95% CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.57 (0.28 - 1.12) 0.104 0.56 (0.28 - 1.12) 0.103
NYHA Class
I 1.00 1.00
II 2.87 (0.65 - 12.58) 0.162 2.86 (0.66 - 12.58) 0.158
III 5.11 (1.15 - 22.73) 0.032 4.97 (1.11 - 22.30) 0.036
IV 6.45 (1.25 - 30.40) 0.026 6.03 (1.09 - 33.33) 0.039
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.39 (0.16 - 0.94) 0.036 0.38 (0.16 - 0.93) 0.034
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.27 (0.79 - 6.46) 0.126 2.33 (0.83 - 6.53) 0.108
θ without covariates (SE) 0.16 (0.18)
θ with covariates (SE) 0.08 (0.20)
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; θ: Heterogeneity parameter;
SE: standard error
Table 6.2: Multivariate regression models for with and without frailty on the incidence
of cardiac tamponade when death is a competing risk.
Without frailty With frailty
Characteristics SHR (95% CI) p-value SHR (95% CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.56 (0.28 - 1.11) 0.096 0.57 (0.36 - 0.88) 0.011
NYHA Class
I 1.00 1.00
II 2.79 (0.64 - 12.22) 0.172 2.87 (0.85 - 9.73) 0.091
III 4.88 (1.11 - 21.76) 0.038 5.11 (1.35 - 19.39) 0.016
IV 6.03 (1.17 - 31.01) 0.032 6.45 (1.25 - 33.35) 0.026
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.40 (0.17 - 0.94) 0.035 0.39 (0.18 - 0.84) 0.016
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.19 (0.76 - 6.33) 0.147 2.27 (0.62 - 8.23) 0.210
θ with covariates (SE) 0.07 (0.16) 0.033
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; SHR: Subdistribution Hazard Ratio; θ: Hetero-
geneity parameter; SE: standard error
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Table 6.3: Multivariate regression models for with and without frailty on the incidence of
constriction when death is a competing risk.
Without frailty With frailty
Characteristics HR (95% CI) p-value HR (95% CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.57 (0.35 - 0.93) 0.025 0.56 (0.34 - 0.91) 0.020
Age (years) 1.00 (0.98 - 1.02) 1.000 1.00 (0.98 - 1.02) 0.685
Gender
Male 1.00 1.00
Female 0.57 (0.33 - 0.97) 0.039 0.54 (0.31 - 0.92) 0.023
NYHA Class
I 1.00 1.00
II 1.23 (0.52 - 2.90) 0.630 1.47 (0.61 - 3.55) 0.394
III 2.55 (1.04 - 6.22) 0.040 3.38 (1.35 - 8.47) 0.010
IV 3.13 (1.12 - 8.70) 0.029 2.61 (0.88 - 7.73) 0.084
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 2.45 (0.59 - 10.23) 0.218 2.76 (0.65 - 11.74) 0.169
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.52 (0.30 - 0.91) 0.021 0.66 (0.37 - 1.16) 0.145
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.52 (0.30 - 0.91) 0.022 0.54 (0.31 - 0.96) 0.035
Palpable pulsus paradoxus
No 1.00 1.00
Yes 0.91 (0.51 - 1.65) 0.768 0.77 (0.41 - 1.44) 0.411
Peripheral oedema
No 1.00 1.00
Yes 1.58 (0.94 - 2.67) 0.084 1.76 (1.01 - 3.06) 0.046
Pulmonary infiltrate
No 1.00 1.00
Yes 1.52 (0.94 - 2.46) 0.086 1.48 (0.90 - 2.43) 0.124
HIV status
Negative 1.00 1.00
Positive 0.50 (0.29 - 0.86) 0.013 0.56 (0.32 - 0.97) 0.040
θ without covariates (SE) 0.95 (0.49) 0.027
θ with covariates (SE) 0.99 (0.56) 0.038
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; θ: Hetero-
geneity parameter; SE: standard error
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Table 6.4: Multivariate regression models for with and without frailty on the incidence
of constriction when death is a competing risk.
Competing risk analysis Clustered competing risk
analysis
Characteristics SHR (95% CI) p-value SHR (95% CI) p-value
Treatment
Placebo 1.00 1.00
Prednisolone 0.56 (0.35 - 0.91) 0.020 0.57 (0.40 - 0.80) 0.001
Age (years) 1.00 (0.98 - 1.02) 0.971 1.00 (0.99 - 1.02) 0.880
Gender
Male 1.00 1.00
Female 0.59 (0.34 - 1.00) 0.052 0.57 (0.37 - 0.87) 0.010
NYHA Class
I 1.00 1.00
II 1.21 (0.51 - 2.85) 0.662 1.20 (0.30 - 4.80) 0.800
III 2.47 (1.01 - 6.01) 0.047 2.50 (0.86 - 7.25) 0.093
IV 2.83 (1.03 - 7.76) 0.043 3.03 (0.81 - 11.43) 0.100
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 2.53 (0.72 - 8.94) 0.149 2.61 (0.66 - 10.35) 0.170
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.54 (0.32 - 0.92) 0.025 0.49 (0.30 - 0.81) 0.005
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.52 (0.30 - 0.92) 0.027 0.52 (0.35 - 0.78) 0.002
Palpable pulsus paradoxus
No 1.00 1.00
Yes 0.93 (0.52 - 1.67) 0.821 0.97 (0.62 - 1.53) 0.900
Peripheral oedema
No 1.00 1.00
Yes 1.55 (0.91 - 2.64) 0.108 1.59 (1.03 - 2.45) 0.037
Pulmonary infiltrate
No 1.00 1.00
Yes 1.52 (0.94 - 2.47) 0.087 1.55 (0.87 - 2.76) 0.140
HIV status
Negative 1.00 1.00
Positive 0.49 (0.28 - 0.86) 0.013 0.52 (0.34 - 0.79) 0.002
θ with covariates (SE) 0.99 (0.56) 0.035
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CI: Confidence Interval; SHR: Subdistribution Hazard
Ratio; θ: Heterogeneity parameter; SE: standard error
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Figure 6.1: Estimated random effect(s) (frailties) for each centre for the (a) cardiac tamponade,
and (b) constriction. Data are from the null model without covariates. Each circle on the plot
represent each centre from the eight African countries namely, South Africa, Mozambique,
Malawi, Nigeria, Sierra Leone, Zimbabwe, Uganda, and Kenya.
6.5 Chapter summary
Due to the complexity of the IMPI clinical trial dataset, we decided to examine the effect of
the recognised risk factors on the outcomes of interest by taking into account the effect of the
competing event and the centres effect. Cause-specific hazards and sub-distribution hazards
models for competing risks have been extended to accommodate a random effect. This was done
by Christian et al. (2016) and Katsahian et al. (2006) respectively. A remarkable heterogeneity
across centres in the rates of constriction as compared to the cardiac tamponade was observed,
but this only slightly changed the estimated effect of the covariates as compared to the Cox
PH model and the Fine and Gray model.
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Chapter 7
Summary, conclusion and further
research
This chapter summarises and concludes this research work. Possible further research is also
suggested in this chapter.
7.1 Summary and conclusion
This thesis analysed the IMPI clinical trial which was carried out in 19 centres in 8 African
countries with the principal objective of assessing the effectiveness and safety of adjunctive pred-
nisolone and M. indicus pranii immunotherapy in reducing the composite outcome of death,
constriction or cardiac tamponade, requiring pericardial drainage in patients with probable
or definite tuberculous pericarditis. During the follow-up period out of 1400 patients, 50 ex-
perienced cardiac tamponade, 85 experience constriction, 246 experienced death of which 18
experienced cardiac tamponade before they died and 23 experienced constriction before they
died. 336 experienced composite outcome which can either be death, cardiac tamponade or
constriction. Using Mann-Whitney and Chi-square test satistics, there were no statistically sig-
nificant differences between the treatments in the baseline characteristics of the patients. This
was important in ensuring there was no allocation bias influencing the effect of the treatment
outcome.
In univariate and multivariate Cox proportional hazards models, we found that age, weight,
New York Heart Association (NYHA) class, hypotension, creatinine, peripheral oedema show a
statistically significant association with the composite outcome. Furthermore, weight, NYHA
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class, hypotension, creatinine and peripheral oedema show a statistically significant association
with death. In addition, NYHA class and hypotension show a statistically significant association
with cardiac tamponade. Lastly, prednisolone, gender, NYHA class, tachycardia, haemoglobin
level, peripheral oedema, pulmonary infiltrate and HIV status show a statistically significant
association with constriction. In an article written by Mayosi et al. (2014) where IMPI clinical
trial data was analysed, these other significant variables were not detected because they only
examined the effect of the treatments groups on the event of interest. The proportionality
assumption check using Schoenfeld residuals shows that the proportionality assumption was
not violated for all the variables. Also, the graph of Cox-Snell residuals indicated the Cox PH
model as a good fit for the data.
In order to understand the centre effect on the incidence of composite outcome (death, cardiac
tamponade or constriction) and the individual outcome, we fitted a multivariate shared gamma
frailty model. There is a significant centre effect on the incidence of constriction (p-value = <
0.001). Furthermore, in making a comparison of shared gamma frailty models with the Cox
PH models, the variables estimate and significance of variables in the event of cardiac tampon-
ade and death, are similar but vary in the event of constriction. The presence of pulmonary
infiltrate was significant in the Cox PH model but, insignificant in the shared frailty effect
model. Also, tachycardia heart rate was not significant in the Cox PH model but significant
in the shared frailty model. These results are likely to be because the frailty effect was highly
significant in the event of constriction compared to other events (p < 0.001). After fitting both
the Cox PH model and the shared gamma frailty model, the goodness of fit of the models was
assessed through residual plots. Both models do not fit the data too badly. A comparison of
the two modelling approaches based on their log-likelihood, AIC and BIC, suggest that the
shared gamma frailty model fits the data better than the Cox PH model.
Also, we explored the use of parametric models, which was done for completion and comparison
purposes since the proportional hazard assumption was satisfied in the Cox PH models. The
hazard ratios for the Cox proportional hazards model and the Weibull model in the propor-
tional hazards framework were very similar. However, the Cox-Snell residuals plot shows that
the overall fit of the Weibull PH model isn’t sufficiently adequate for the data. The result from
the Weibull frailty models indicates a high amount of variation in the incidence of constriction
but not in the incidence of death nor cardiac tamponade. Again these results are similar to
the Cox frailty models presented in Chapter three of this thesis. For the AFT models, the
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log-normal distribution appeared to have the best model fit as compared to other distributions
commonly used in the AFT model. The Cox-Snell residuals plot shows that the overall fit of
the lognormal AFT model is not sufficiently adequate for the data.
We proceeded with the competing risk analysis because there is a need to examine the contribu-
tion of competing risks analyses in the composite outcome setting; reasons for this were earlier
discussed. We considered death as a competing risk to the event of cardiac tamponade and
constriction since a patient can die before experiencing these events. Two main modelling ap-
proaches in competing risks settings, (cause-specific and sub-distribution hazards), were used.
In both analyses, the patient in NYHA class one that had hypotension of >90 mmHg, had a
lower hazard or sub-hazard of cardiac tamponade. Also, the patient who received prednisolone
treatment compared to those who received placebo, female patients, patients that are in NHYA
class one, had tachycardia (heart rate) >100 mmHg, haemoglobin level that is <10 g/dl and is
HIV-positive, had lower hazard or sub-hazard of constriction. The effect estimates of covariates
on the cause-specific hazard function and the sub-distribution hazard function are fairly similar.
The estimates of these risk factors from the standard Cox proportional hazards models are the
same as the estimates obtained from the analysis, using a cause-specific hazards function. This
result is inevitable because a cause-specific hazards function treats competing events as being
censored. In this thesis, the result of competing risks analysis has limited power because the
IMPI trial was designed to study a composite outcome and not powered to study competing
risks.
In the analysis of clustered competing risks, there is a significant centre effect in the incidence
of constriction (p-value = <0.001). The observed heterogeneity across centres in the rates of
constriction is remarkably large in contrast to the heterogeneity in the rates of cardiac tam-
ponade. In comparison with the model from the competing risks that does not account for the
centre effect, we observed that the covariate effect was only slightly changed. However, in the
incidence of constriction, the presence of pulmonary infiltrate was significant in the compet-
ing risk model (without frailty) but, insignificant in the clustered competing risk model (with
frailty). Also, the tachycardia heart rate was not significant in the competing risk model but
significant in the clustered competing risk model.
In conclusion, a comparison of the modelling approaches using different statistical techniques
suggests that the models which take into account the random effect are better than those that
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do not, especially in the incidence of constriction. This is based on the significant result of the
clustering parameter (theta).
7.2 Further research
A further area of research would be to conduct analysis of HIV-positive patients only, since
these patients are more sick. Furthermore, other competing risks models such as the binomial
regression, pseudo-value, and the multi-state modelling approach could be used. In addition,
bivariate competing risks in which constriction and cardiac tamponade would be considered
together against death, as a competing event using copulas or the Bayesian method, can be
performed. Also, of interest would be to examine the effect of time-varying covariates such as
the CD4 count or ART treatment in the competing risk setting(s).
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Appendix A
Analyses of data for patients who
received M. indicus pranii only
The appendix presents the results of the analysis which include M. indicus pranii treatment
and its placebo group. The interpretation of the models is the same as the presented models
in the application sections that included prednisolone treatment and its placebo group.
Figure A.1: Estimated survival function for M. indicus pranii and placebo group until the end
of study. (a) composite outcome, (b) death, (c) constriction, (d) cardiac tamponade.
81
Figure A.2: Estimated survival function for M. indicus pranii and placebo group at 6 months
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A.1 Cox proportional hazards models
Table A.1: Univariate and multivariate Cox PH model for the relative hazard of the
composite outcome.
Univariate analysis Multivariate analysis
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.02 (0.82 - 1.28) 0.857 1.12 (0.87 - 1.45) 0.379
Age (years) 1.00 (1.00 - 1.02) 0.030 1.01 (0.99 - 1.02) 0.092
Weight (kg) 0.91 (0.83 - 1.00) 0.042 0.89 (0.79 - 0.99) 0.031
NYHA Class
I 1.00 1.00
II 1.63 (1.12 - 2.37) 0.010 1.44 (0.91 - 2.27) 0.121
III 2.73 (1.86 - 4.01) <0.001 2.27 (1.38 - 3.72) 0.001
IV 3.24 (2.08 - 5.07) <0.001 2.49 (1.42 - 4.35) 0.001
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.59 (0.42 - 0.82) 0.002 0.73 (0.49 - 1.10) 0.132
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.75 (0.60 - 0.93) 0.011 0.80 (0.61 - 1.05) 0.115
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.51 (1.12 - 2.05) 0.006 1.76 (1.24 - 2.51) 0.002
Palpable pulsus paradoxus
No 1.00 1.00
Yes 1.47 (1.15 - 1.88) 0.002 0.92 (0.67 - 1.27) 0.625
Peripheral oedema
No 1.00 1.00
Yes 1.75 (1.41 - 2.17) <0.001 1.52 (1.16 - 1.98) 0.002
Pulmonary infiltrate on CXR
No 1.00 1.00
Yes 1.23 (0.97 - 1.55) 0.087 1.12 (0.86 - 1.46) 0.399
Effusion size
small 1.00 1.00
medium 1.57 (0.93 - 2.64) 0.093 1.76 (0.91 - 3.39) 0.094
large 1.64 (1.00 - 2.69) 0.048 1.63 (0.87 - 3.04) 0.127
AIC 3148.256
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR: Chest Xray.
CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information Criterion
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Table A.2: Univariate and multivariate Cox PH model for the relative hazard of
death.
Univariate analysis Multivariate analysis
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.06 (0.82 - 1.38) 0.652 1.01 (0.78 - 1.34) 0.922
Weight (kg) 0.85 (0.76 - 0.96) 0.006 0.87 (0.77 - 1.97) 0.024
NYHA Class
I 1.00 1.00
II 1.42 (0.93 - 2.16) 0.107 1.21 (0.74 - 1.97) 0.456
III 2.20 (1.42 - 3.43) <0.001 1.79 (1.07 - 3.00) 0.027
IV 3.14 (1.91 - 5.16) <0.001 2.45 (1.38 - 4.34) 0.002
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.45 (0.31 - 0.64) <0.001 0.57 (0.38 - 0.85) 0.006
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.79 (1.28 - 2.52) 0.001 1.94 (1.35 - 2.77) <0.001
Peripheral oedema
No 1.00 1.00
Yes 1.57 (1.23 - 2.02) <0.001 1.43 (1.07 - 1.92) 0.016
AIC 2663.553
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s
Information Criterion
Table A.3: Univariate and multivariate Cox PH model for the relative hazard of cardiac
tamponade.
Univariate analysis Multivariate analysis
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.00 (0.55 - 1.81) 0.999 1.04 (0.50 - 2.16) 0.912
NYHA Class
I 1.00 1.00
II 3.04 (0.92 - 10.10) 0.069 2.61 (0.59 - 11.61) 0.207
III 4.65 (1.36 - 15.87) 0.014 4.65 (1.03 - 21.03) 0.046
IV 4.86 (1.21 - 19.43) 0.025 3.96 (0.66 - 23.78) 0.133
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.36 (0.17 - 0.74) 0.005 0.38 (0.14 - 0.99) 0.049
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.41 (0.85 - 6.82) 0.098 2.69 (0.93 - 7.80) 0.069
AIC 393.249
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information
Criterion
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Table A.4: Univariate and multivariate Cox PH model for the relative hazard of the
constriction.
Univariate analysis Multivariate analysis
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 0.98 (0.62 - 1.55) 0.922 1.10 (0.67 - 1.81) 0.703
Age (years) 1.01 (1.00 - 1.03) 0.046 1.00 (0.98 - 1.02) 0.872
Gender
Male 1.00 1.00
Female 0.52 (0.32 - 0.82) 0.005 0.48 (0.27 - 0.86) 0.013
NYHA Class
I 1.00 1.00
II 1.93 (0.86 - 4.36) 0.111 1.33 (0.53 - 3.30) 0.544
III 3.85 (1.70 - 8.72) 0.001 2.53 (0.97 - 6.60) 0.059
IV 3.97 (1.54 - 10.24) 0.004 2.70 (0.90 - 8.13) 0.077
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 3.26 (0.80 - 13.27) 0.098 2.45 (0.59 - 10.22) 0.220
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.46 (0.29 - 0.75) 0.002 0.47 (0.26 - 0.84) 0.010
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.40 (0.26 - 0.64) <0.001 0.43 (0.24 - 0.80) 0.007
Palpable pulsus paradoxus
No 1.00 1.00
Yes 1.99 (1.26 - 3.14) 0.003 1.24 (0.68 - 2.27) 0.485
Peripheral oedema
No 1.00 1.00
Yes 2.54 (1.64 - 3.94) <0.001 1.63 (0.94 - 2.83) 0.081
Pulmonary infiltrate
No 1.00 1.00
Yes 1.49 (0.94 - 2.37) 0.090 1.50 (0.90 - 2.49) 0.120
HIV status
Negative 1.00 1.00
Positive 0.41 (0.27 - 0.63) <0.001 0.60 (0.34 - 1.07) 0.082
AIC 834.157
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC:Akaike’s Information
Criterion
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A.2 Shared frailty models
Table A.5: Multivariable shared frailty model for the relative haz-
ard of the composite outcome.
Characteristics HR (95%CI) p-value
Treatment
Placebo 1.00
M. indicus pranii 1.11 (0.86 - 1.44) 0.421
Age (years) 1.01 (0.99 - 1.02) 0.100
Weight (kg) 0.88 (0.79 - 0.99) 0.027
NYHA Class
I 1.00
II 1.41 (0.89 - 2.24) 0.149
III 2.19 (1.32 - 3.64) 0.002
IV 2.07 (1.16 - 3.69) 0.014
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 0.74 (0.49 - 1.12) 0.156
Tachycardia (HR)
≤ 100 mmHg 1.00
> 100 mmHg 0.85 (0.65 - 1.12) 0.253
Creatinine
≤ 105 umol/l 1.00
> 105 umol/l 1.78 (1.25 - 2.54) 0.002
Palpable pulsus paradoxus
No 1.00
Yes 0.94 (0.67 - 1.32) 0.736
Peripheral oedema
No 1.00
Yes 1.65 (1.24 - 2.20) 0.001
Pulmonary infiltrate on CXR
No 1.00
Yes 1.15 (0.88 - 1.51) 0.313
Effusion size
small 1.00
medium 1.66 (0.86 - 3.23) 0.134
large 1.55 (0.82 - 2.92) 0.177
θ (SE) 0.117 (0.090) 0.012
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR: Chest Xray.
CI: Confidence Interval; HR: Hazard Ratio; SE: Standard Error; θ: Heterogeneity parameter
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Table A.6: Multivariable shared frailty model for
the relative hazard of the death outcome.
Characteristics HR (95%CI) p-value
Treatment
Placebo 1.00
M. indicus pranii 1.01 (0.76 - 1.34) 0.942
Weight (kg) 0.87 (0.77 - 0.98) 0.021
NYHA Class
I 1.00
II 1.16 (0.71 - 1.90) 0.558
III 1.70 (1.01 - 2.90) 0.047
IV 2.27 (1.27 - 4.08) 0.006
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 0.57 (0.38 - 0.86) 0.008
Creatinine
≤ 105 umol/l 1.00
> 105 umol/l 1.91 (1.34 - 2.74) <0.001
Peripheral oedema
No 1.00
Yes 1.53 (1.13 - 2.09) 0.006
θ (SE) 0.036 (0.042) 0.099
NYHA: New York Heart Association; SBP: Systolic Blood Pressure
CI: Confidence Interval; HR: Hazard Ratio; SE: Standard Error; θ: Heterogeneity
parameter
Table A.7: Multivariable shared frailty model for the relative
hazard of cardiac tamponade outcome.
Characteristics HR (95%CI) p-value
Treatment
Placebo 1.00
M. indicus pranii 1.05 (0.51 - 2.19) 0.887
NYHA Class
I 1.00
II 2.40 (0.53 - 10.85) 0.255
III 3.98 (0.86 - 18.50) 0.078
IV 2.86 (0.46 - 17.89) 0.262
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 0.36 (0.14 - 0.98) 0.045
Atrial fibrillation on ECG
No 1.00
Yes 2.63 (0.91 - 7.67) 0.076
θ (SE) 0.241 (0.291) 0.112
NYHA: New York Heart Association; SBP: Systolic Blood Pressure
CI: Confidence Interval; HR: Hazard Ratio; SE: Standard Error; θ: Heterogeneity parameter
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Table A.8: Multivariable shared frailty model for the relative
hazard of constriction.
Characteristics HR (95%CI) p-value
Treatment
Placebo 1.00
M. indicus pranii 1.10 (0.66 - 1.81) 0.722
Age (years) 1.00 (0.98 - 1.03) 0.674
Gender
Male 1.00
Female 0.46 (0.25 - 0.83) 0.009
NYHA Class
I 1.00
II 1.66 (0.65 - 4.23) 0.290
III 3.51 (1.32 - 9.35) 0.012
IV 2.26 (0.70 - 7.31) 0.174
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 2.50 (0.59 - 10.68) 0.215
Tachycardia (HR)
≤ 100 mmHg 1.00
> 100 mmHg 0.64 (0.36 - 1.16) 0.144
Haemoglobin
≤ 10 g/dl 1.00
> 10 g/dl 0.48 (0.26 - 0.88) 0.019
Palpable pulsus paradoxus
No 1.00
Yes 0.99 (0.52 - 1.93) 0.995
Peripheral oedema
No 1.00
Yes 1.84 (1.01 - 3.33) 0.045
Pulmonary infiltrate
No 1.00
Yes 1.41 (0.83 - 2.41) 0.206
HIV status
Negative 1.00
Positive 0.63 (0.35 - 1.15) 0.132
θ (SE) 0.1.316 (0.751) <0.001
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure
CI: Confidence Interval; HR: Hazard Ratio; SE: Standard Error; θ: Heterogeneity parameter
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A.3 Parametric proportional hazards models
Table A.9: Weibull proportional hazards models with and without frailty in the composite
outcome.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.13 (0.87 - 1.46) 0.350 1.12 (0.86 - 1.44) 0.400
Age (years) 1.01 (1.00 - 1.02) 0.079 1.01 (1.00 - 1.02) 0.078
Weight (kg) 0.88 (0.79 - 0.98) 0.022 0.87 (0.78 - 0.98) 0.018
NYHA Class
I 1.00 1.00
II 1.37 (0.87 - 2.17) 0.173 1.35 (0.85 - 2.15) 0.207
III 2.19 (1.33 - 3.60) 0.002 2.12 (1.28 - 3.52) 0.004
IV 2.41 (1.38 - 4.22) 0.002 1.98 (1.10 - 3.56) 0.023
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.73 (0.48 - 1.09) 0.120 0.73 (0.48 - 1.10) 0.133
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.80 (0.61 - 1.05) 0.108 0.85 (0.64 - 1.12) 0.254
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.80 (1.26 - 2.55) 0.001 1.81 (1.27 - 2.59) 0.001
Palpable pulsus paradoxus
No 1.00 1.00
Yes 0.91 (0.66 - 1.25) 0.561 0.93 (0.66 - 1.30) 0.660
Peripheral oedema
No 1.00 1.00
Yes 1.53 (1.17 - 2.00) 0.002 1.68 (1.25 - 2.25) 0.001
Pulmonary infiltrate on CXR
No 1.00 1.00
Yes 1.14 (0.87 - 1.48) 0.350 1.16 (0.89 - 1.53) 0.275
Effusion size
small 1.00 1.00
medium 1.75 (0.91 - 3.39) 0.096 1.64 (0.84 - 3.20) 0.145
large 1.66 (0.89 - 3.10) 0.114 1.56 (0.83 - 2.94) 0.171
θ (SE) 0.135 (0.100) 0.007
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR: Chest Xray.
CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information Criterion
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Table A.10: Weibull proportional hazards models with and without frailty in death
outcome.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.02 (0.77 - 1.34) 0.908 1.01 (0.77 - 1.34) 0.926
Weight (kg) 0.87 (0.77 - 0.98) 0.019 0.86 (0.76 - 0.97) 0.016
NYHA Class
I 1.00 1.00
II 1.18 (0.72 - 1.93) 0.513 1.14 (0.69 - 1.87) 0.615
III 1.77 (1.06 - 2.96) 0.030 1.68 (1.00 - 2.84) 0.052
IV 2.39 (1.35 - 4.23) 0.003 2.21 (1.22 - 4.00) 0.009
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.56 (0.38 - 0.85) 0.006 0.57 (0.38 - 0.86) 0.007
Creatinine
≤ 105 umol/l 1.00 1.00
> 105 umol/l 1.94 (1.36 - 2.77) <0.001 1.91 (1.34 - 2.74) 0.<0.001
Peripheral oedema
No 1.00 1.00
Yes 1.44 (1.08 - 1.93) 0.014 1.55 (1.13 - 2.12) 0.007
θ (SE) 0.038 (0.044) 0.090
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s
Information Criterion
Table A.11: Weibull proportional hazards models with and without frailty in the cardiac
tamponade outcome.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.05 (0.51 - 2.19) 0.886 1.07 (0.52 - 2.22) 0.857
NYHA Class
I 1.00 1.00
II 2.56 (0.58 - 11.36) 0.217 2.34 (0.52 - 10.56) 0.270
III 4.46 (0.99 - 20.16) 0.052 3.77 (0.81 - 17.60) 0.091
IV 3.85 (0.64 - 23.10) 0.141 2.63 (0.39 - 17.85) 0.321
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.37 (0.14 - 0.96) 0.041 0.34 (0.13 - 0.93) 0.035
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.79 (0.96 - 8.10) 0.059 2.75 (0.94 - 8.01) 0.064
θ (SE) 0.301 (0.323) 0.074
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information
Criterion
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Table A.12: Weibull proportional hazards models with and without frailty in the con-
striction outcome.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.14 (0.69 - 1.87) 0.616 1.11 (0.67 - 1.84) 0.673
Age (years) 1.00 (0.98 - 1.02) 0.836 1.00 (0.98 - 1.03) 0.642
Gender
Male 1.00 1.00
Female 0.46 (0.26 - 0.82) 0.009 0.45 (0.25 - 0.80) 0.007
NYHA Class
I 1.00 1.00
II 1.18 (0.47 - 2.95) 0.724 1.42 (0.56 - 3.64) 0.462
III 2.38 (0.90 - 6.24) 0.079 3.17 (1.19 - 8.45) 0.021
IV 2.46 (0.82 - 7.40) 0.108 2.06 (0.64 - 6.61) 0.224
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 2.24 (0.54 - 9.32) 0.269 2.29 (0.54 - 9.71) 0.263
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.46 (0.26 - 0.81) 0.007 0.63 (0.35 - 1.15) 0.132
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.42 (0.23 - 0.78) 0.006 0.48 (0.26 - 0.89) 0.020
Palpable pulsus paradoxus
No 1.00 1.00
Yes 1.18 (0.65 - 2.17) 0.584 0.93 (0.48 - 1.80) 0.840
Peripheral oedema
No 1.00 1.00
Yes 1.65 (0.95 - 2.86) 0.073 1.83 (1.01 - 3.31) 0.047
Pulmonary infiltrate
No 1.00 1.00
Yes 1.53 (0.92 - 2.55) 0.101 1.44 (0.85 - 2.45) 0.178
HIV status
Negative 1.00 1.00
Positive 0.62 (0.35 - 1.10) 0.100 0.63 (0.34 - 1.15) 0.131
θ (SE) 1.325 (0.759) < 0.001
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC:Akaike’s Information
Criterion
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A.4 Accelerated Failure Models
Table A.13: Log-normal accelerated failure time model for
the composite outcome.
AFT analysis
Characteristics TR (95%CI) p-value
Treatment
Placebo 1.00
M. indicus pranii 0.79 (0.45 - 1.39) 0.409
Age (years) 0.98 (0.96 - 1.00) 0.077
Weight (kg) 1.27 (0.99 - 1.62) 0.057
NYHA Class
I 1.00
II 0.42 (0.17 - 1.04) 0.061
III 0.16 (0.06 - 0.45) <0.001
IV 0.14 (0.04 - 0.49) 0.02
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 1.67 (0.63 - 4.46) 0.304
Tachycardia (HR)
≤ 100 mmHg 1.00
> 100 mmHg 1.71 (0.94 - 3.10) 0.077
Creatinine
≤ 105 umol/l 1.00
> 105 umol/l 0.30 (0.13 - 0.69) 0.005
Palpable pulsus paradoxus
No 1.00
Yes 1.08 (0.52 - 2.24) 0.843
Peripheral oedema
No 1.00
Yes 0.41 (0.22 - 0.74) 0.003
Pulmonary infiltrate on CXR
No 1.00
Yes 0.87 (0.48 - 1.58) 0.653
Effusion size
small 1.00
medium 0.34 (0.09 - 1.31) 0.118
large 0.44 (0.12 - 1.53) 0.195
NYHA: New York Heart Association; HR: Heart Rate; SBP: Systolic Blood Pressure; CXR: Chest
Xray.
CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information Criterion
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Table A.14: Log-normal accelerated failure time
model for the death outcome.
AFT analysis
Characteristics TR (95%CI) p-value
Treatment
Placebo 1.00
M. indicus pranii 0.92 (0.53 - 1.60) 0.762
Weight (kg) 1.25 (0.99 - 1.57) 0.066
NYHA Class
I 1.00
II 0.63 (0.26 - 1.51) 0.297
III 0.30 (0.11 - 0.78) 0.014
IV 0.17 (0.05 - 0.54) 0.003
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 2.92 (1.17 - 7.32) 0.022
Creatinine
≤ 105 umol/l 1.00
> 105 umol/l 0.27 (0.12 - 0.58) 0.001
Peripheral oedema
No 1.00
Yes 0.48 (0.27 - 0.85) 0.013
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confi-
dence Interval; HR: Hazard Ratio; AIC: Akaike’s Information Criterion
Table A.15: Log-normal accelerated failure time model for
the cardiac tamponade outcome.
AFT analysis
Characteristics TR (95%CI) p-value
Treatment
Placebo 1.00
M. indicus pranii 1.12 (0.13 - 9.83) 0.917
NYHA Class
I 1.00
II 0.09 (0.002 - 4.34) 0.226
III 0.02 (0.0003 - 0.99) 0.049
IV 0.03 (0.0002 - 5.11) 0.185
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 16.77 (0.57 - 491.27) 0.096
Atrial fibrillation on ECG
No 1.00
Yes 0.04 (0.001 - 1.75) 0.999
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR:
Hazard Ratio; AIC: Akaike’s Information Criterion
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Table A.16: Log-normal accelerated failure time model for
the constriction outcome.
AFT analysis
Characteristics TR (95%CI) p-value
Treatment
Placebo 1.00
M. indicus pranii 0.69 (0.20 - 2.36) 0.552
Age (years) 0.99 (0.95 - 1.04) 0.680
Gender
Male 1.00
Female 6.61 (1.62 - 27.02) 0.009
NYHA Class
I 1.00
II 0.49 (0.06 - 3.70) 0.486
III 0.11 (0.01 - 1.06) 0.057
IV 0.11 (0.01 - 1.66) 0.112
Hypotension (SBP)
≤ 90 mmHg 1.00
> 90 mmHg 0.10 (0.004 - 2.94) 0.185
Tachycardia (HR)
≤ 100 mmHg 1.00
> 100 mmHg 6.07 (1.53 - 24.02) 0.010
Haemoglobin
≤ 10 g/dl 1.00
> 10 g/dl 6.13 (1.45 - 25.79) 0.013
Palpable pulsus paradoxus
No 1.00
Yes 0.61 (0.13 - 2.93) 0.538
Peripheral oedema
No 1.00
Yes 0.31 (0.08 - 1.18) 0.087
Pulmonary infiltrate
No 1.00
Yes 0.49 (0.13 - 1.80) 0.284
HIV status
Negative 1.00
Positive 3.84 (0.93 - 15.85) 0.063
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval;
HR: Hazard Ratio; AIC:Akaike’s Information Criterion
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A.5 Cumulative incidence function
Figure A.3: Estimated cumulative incidence function for M. indicus pranii and placebo group
from the beginning of study until the end of the study. (a) constriction, (b) cardiac tamponade
Figure A.4: Estimated cumulative incidence function for M. indicus pranii and placebo group
from the beginning of study until 6 months. (c) constriction, (d) cardiac tamponade
95
A.6 Competing risks models
Table A.17: Multivariate regression models on the cause-specific hazards function and
sub-distribution hazards function on the relative hazard of cardiac tamponade when death
is a competing event.
Sub-distribution hazards Cause-specific hazards
Characteristics SHR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.04 (0.51 - 2.12) 0.919 1.04 (0.50 - 2.16) 0.912
NYHA Class
I 1.00 1.00
II 2.53 (0.57 - 11.19) 0.222 2.61 (0.59 - 11.61) 0.207
III 4.43 (0.98 - 20.05) 0.053 4.65 (1.03 - 21.03) 0.046
IV 3.76 (0.63 - 22.39) 0.145 3.96 (0.66 - 23.78) 0.133
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.39 (0.15 - 0.99) 0.005 0.38 (0.14 - 0.99) 0.049
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.50 (0.83 - 7.53) 0.104 2.69 (0.93 - 7.80) 0.069
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information
Criterion
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Table A.18: Multivariate regression models on the cause-specific hazards function and
sub-distribution hazards function on the relative hazard of constriction when death is a
competing event.
Sub-distribution hazards Cause-specific hazards
Characteristics SHR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.10 (0.67 - 1.80) 0.715 1.10 (0.67 - 1.81) 0.703
Age (years) 1.00 (0.98 - 1.03) 0.894 1.00 (0.98 - 1.02) 0.872
Gender
Male 1.00 1.00
Female 0.50 (0.28 - 0.90) 0.021 0.48 (0.27 - 0.86) 0.013
NYHA Class
I 1.00 1.00
II 1.30 (0.52 - 3.26) 0.581 1.33 (0.53 - 3.30) 0.544
III 2.46 (0.93 - 6.48) 0.069 2.53 (0.97 - 6.60) 0.059
IV 2.45 (0.82 - 7.40) 0.111 2.70 (0.90 - 8.13) 0.077
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 2.46 (0.68 - 8.95) 0.171 2.45 (0.59 - 10.22) 0.220
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.49 (0.28 - 0.86) 0.013 0.47 (0.26 - 0.84) 0.010
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.43 (0.24 - 0.83) 0.009 0.43 (0.24 - 0.80) 0.007
Palpable pulsus paradoxus
No 1.00 1.00
Yes 1.27 (0.71 - 2.27) 0.420 1.24 (0.68 - 2.27) 0.485
Peripheral oedema
No 1.00 1.00
Yes 1.54 (0.89 - 2.70) 0.131 1.63 (0.94 - 2.83) 0.081
Pulmonary infiltrate
No 1.00 1.00
Yes 1.47 (0.88 - 2.46) 0.140 1.50 (0.90 - 2.49) 0.120
HIV status
Negative 1.00 1.00
Positive 0.60 (0.33 - 1.07) 0.084 0.60 (0.34 - 1.07) 0.082
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC:Akaike’s Information
Criterion
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A.7 Clustered competing risks
Table A.19: Multivariate regression models for with and without frailty on the incidence
of cardiac tamponade when death is a competing risk.
Without frailty With frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.04 (0.50 - 2.16) 0.912 1.07 (0.51 - 2.21) 0.865
NYHA Class
I 1.00 1.00
II 2.61 (0.59 - 11.61) 0.207 2.44 (0.54 - 11.02) 0.245
III 4.65 (1.03 - 21.03) 0.046 4.01 (0.86 - 18.72) 0.077
IV 3.96 (0.66 - 23.78) 0.133 3.01 (0.45 - 20.20) 0.256
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.38 (0.14 - 0.99) 0.049 0.36 (0.13 - 0.94) 0.037
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.69 (0.93 - 7.80) 0.069 2.76 (0.95 - 8.01) 0.062
θ (SE) 0.259 (0.300) 0.195
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information
Criterion
Table A.20: Multivariate regression models for with and without frailty on the incidence
of cardiac tamponade when death is a competing risk.
Without frailty With frailty
Characteristics SHR (95%CI) p-value SHR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.04 (0.51 - 2.12) 0.919 1.04 (0.54 - 2.01) 0.900
NYHA Class
I 1.00 1.00
II 2.53 (0.57 - 11.19) 0.222 2.61 (0.81 - 8.55) 0.110
III 4.43 (0.98 - 20.05) 0.053 4.65 (1.32 - 16.34) 0.017
IV 3.76 (0.63 - 22.39) 0.145 3.96 (0.82 - 19.18) 0.088
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 0.39 (0.15 - 0.99) 0.005 0.38 (0.16 - 0.87) 0.023
Atrial fibrillation on ECG
No 1.00 1.00
Yes 2.50 (0.83 - 7.53) 0.104 2.69 (0.65 - 11.14) 0.170
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC: Akaike’s Information
Criterion
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Table A.21: Multivariate regression models for with and without frailty on the incidence
of constriction when death is a competing risk.
With frailty Without frailty
Characteristics HR (95%CI) p-value HR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.09 (0.66 - 1.80) 0.730 1.10 (0.67 - 1.81) 0.703
Age (years) 1.00 (0.98 - 1.03) 0.894 1.00 (0.98 - 1.02) 0.685
Gender
Male 1.00 1.00
Female 0.45 (0.25 - 0.82) 0.008 0.48 (0.27 - 0.86) 0.013
NYHA Class
I 1.00 1.00
II 1.65 (0.65 - 4.22) 0.294 1.33 (0.53 - 3.30) 0.544
III 3.52 (1.32 - 9.40) 0.012 2.53 (0.97 - 6.60) 0.059
IV 2.30 (0.71 - 7.45) 0.165 2.70 (0.90 - 8.13) 0.077
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 2.51 (0.59 - 10.69) 0.212 2.45 (0.59 - 10.22) 0.220
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.64 (0.35 - 1.16) 0.144 0.47 (0.26 - 0.84) 0.010
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.48 (0.26 - 0.88) 0.018 0.43 (0.24 - 0.80) 0.007
Palpable pulsus paradoxus
No 1.00 1.00
Yes 0.99 (0.51 - 1.91) 0.978 1.24 (0.68 - 2.27) 0.485
Peripheral oedema
No 1.00 1.00
Yes 1.82 (1.01 - 3.31) 0.048 1.63 (0.94 - 2.83) 0.081
Pulmonary infiltrate
No 1.00 1.00
Yes 1.42 (0.83 - 2.42) 0.199 1.50 (0.90 - 2.49) 0.120
HIV status
Negative 1.00 1.00
Positive 0.63 (0.35 - 1.15) 0.132 0.60 (0.34 - 1.07) 0.082
θ (SE) 1.305 (0.746) 0.040
NYHA: New York Heart Association; SBP: Systolic Blood Pressure; CI: Confidence Interval; HR: Hazard Ratio; AIC:Akaike’s Information
Criterion
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Table A.22: Multivariate regression models for with and without frailty on the incidence
of constriction when death is a competing risk.
Without frailty With frailty
Characteristics SHR (95%CI) p-value SHR (95%CI) p-value
Treatment
Placebo 1.00 1.00
M. indicus pranii 1.10 (0.67 - 1.80) 0.715 1.10 (0.85 - 1.44) 0.470
Age (years) 1.00 (0.98 - 1.03) 0.894 1.00 (0.98 - 1.02) 0.860
Gender
Male 1.00 1.00
Female 0.50 (0.28 - 0.90) 0.021 0.48 (0.28 - 0.82) 0.007
NYHA Class
I 1.00 1.00
II 1.30 (0.52 - 3.26) 0.581 1.33 (0.34 - 5.11) 0.680
III 2.46 (0.93 - 6.48) 0.069 2.53 (0.96 - 6.62) 0.059
IV 2.45 (0.82 - 7.40) 0.111 2.70 (0.76 - 9.57) 0.120
Hypotension (SBP)
≤ 90 mmHg 1.00 1.00
> 90 mmHg 2.46 (0.68 - 8.95) 0.171 2.45 (0.62 - 9.73) 0.200
Tachycardia (HR)
≤ 100 mmHg 1.00 1.00
> 100 mmHg 0.49 (0.28 - 0.86) 0.013 0.47 (0.26 - 0.84) 0.010
Haemoglobin
≤ 10 g/dl 1.00 1.00
> 10 g/dl 0.43 (0.24 - 0.83) 0.009 0.43 (0.28 - 0.67) <0.001
Palpable pulsus paradoxus
No 1.00 1.00
Yes 1.27 (0.71 - 2.27) 0.420 1.24 (0.79 - 1.95) 0.350
Peripheral oedema
No 1.00 1.00
Yes 1.54 (0.89 - 2.70) 0.131 1.63 (1.07 - 2.50) 0.024
Pulmonary infiltrate
No 1.00 1.00
Yes 1.47 (0.88 - 2.46) 0.140 1.50 (0.73 - 3.08) 0.270
HIV status
Negative 1.00 1.00
Positive 0.60 (0.33 - 1.07) 0.084 0.60 (0.37 - 0.98) 0.043





In this section the STATA and R-code used for analysis of the data from the IMPI clinical trial,
which is presented in this thesis, is sketched. Some of the variables considered:
• time: Event time or censoring time in the standard survival analysis settings
• status: Indicating type of event or a censored observation in the standard survival analysis
settings
1 = composite, death, cardiac tamponade, or constriction
0 = censored
• Time: Event time or censoring time in the competing risk settings
• Status: Indicating type of event or a censored observation in the competing risk settings
1 = cardiac tamponade, or constriction
2 = death
0 = censored
• Group: Indicating treatment group
1 = prednisolone or M.indicus pranii
0 = placebo
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B.1 Cox proportional hazards models
• Cox model
stset time, failure(status)
stcox group i.Nyhaclass Syblood ecgrthm4
• Shared frailty models
stcox group i.Nyhaclass Syblood ecgrthm4, shared(centre)
B.2 Parametric proportional hazards models
• Without frailty (centre effect)
streg group i.Nyhaclass Syblood ecgrthm4, dist(weibull)
• With frailty (centre effect)
streg group i.Nyhaclass Syblood ecgrthm4, d(weibull) frailty(gamma) shared(centre)
B.3 Accelerated failure time models
streg group i.Nyhaclass Syblood ecgrthm4, dist(lognormal) time
B.4 Competing risk models
• Cause-specific hazard model
stset Time, failure(Status=1)
stcox pred i.Nyhaclass Syblood ecgrthm4
• Sub-distribution hazards model
stcrreg pred i.Nyhaclass Syblood ecgrthm4, compete(Status == 2)
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B.5 Clustered competing risk models
• Cause-specific hazards model with frailty (centre effect)
library(cmprsk); library(frailtypack)
source("C:/Users/Desktop/crr-addson.R")
cov <- cbind(group, factor2ind(Nyhaclass, 1), Syblood, ecgrthm4)
fit <- frailtyPenal(Surv(Time, Status==1) ~ cluster(centre) + cov,
data=Data, n.knots=6, kappa=10000, Frailty=TRUE, cross.validation=TRUE)
• Sub-distribution hazards model with frailty (centre effect)
library(crrSC)
fit <- crrc(Time, Status==1, cov, cluster=centre, failcode=1, na.action=na.omit)
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